US20220042988A1 - Rapid diagnosis of peritonitis in peritoneal dialysis patients - Google Patents
Rapid diagnosis of peritonitis in peritoneal dialysis patients Download PDFInfo
- Publication number
- US20220042988A1 US20220042988A1 US17/498,481 US202117498481A US2022042988A1 US 20220042988 A1 US20220042988 A1 US 20220042988A1 US 202117498481 A US202117498481 A US 202117498481A US 2022042988 A1 US2022042988 A1 US 2022042988A1
- Authority
- US
- United States
- Prior art keywords
- peritoneal dialysis
- subject
- binding molecule
- antigen
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000502 dialysis Methods 0.000 title claims abstract description 89
- 206010034674 peritonitis Diseases 0.000 title claims abstract description 75
- 238000003745 diagnosis Methods 0.000 title claims description 8
- 239000000427 antigen Substances 0.000 claims abstract description 73
- 108091007433 antigens Proteins 0.000 claims abstract description 73
- 102000036639 antigens Human genes 0.000 claims abstract description 73
- 230000027455 binding Effects 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 58
- 208000015181 infectious disease Diseases 0.000 claims abstract description 54
- 241000894006 Bacteria Species 0.000 claims abstract description 41
- 244000052769 pathogen Species 0.000 claims abstract description 28
- 238000003149 assay kit Methods 0.000 claims abstract description 26
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 22
- 239000003550 marker Substances 0.000 claims abstract description 19
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 18
- 241000233866 Fungi Species 0.000 claims abstract description 13
- 239000000872 buffer Substances 0.000 claims abstract description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 52
- 108090001005 Interleukin-6 Proteins 0.000 claims description 52
- 102000013519 Lipocalin-2 Human genes 0.000 claims description 52
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 52
- 239000002158 endotoxin Substances 0.000 claims description 39
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 39
- 230000003115 biocidal effect Effects 0.000 claims description 24
- 239000003242 anti bacterial agent Substances 0.000 claims description 20
- 210000004303 peritoneum Anatomy 0.000 claims description 17
- 230000028709 inflammatory response Effects 0.000 claims description 13
- 241000191967 Staphylococcus aureus Species 0.000 claims description 11
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 10
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- 241000192125 Firmicutes Species 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000004890 Interleukin-8 Human genes 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 9
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 9
- 108010013639 Peptidoglycan Proteins 0.000 claims description 9
- 108010048233 Procalcitonin Proteins 0.000 claims description 9
- 229940100601 interleukin-6 Drugs 0.000 claims description 9
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 7
- 229940096397 interleukin-8 Drugs 0.000 claims description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 108010059993 Vancomycin Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229960003165 vancomycin Drugs 0.000 claims description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 241000194022 Streptococcus sp. Species 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 38
- 238000012360 testing method Methods 0.000 description 88
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 59
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 36
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 36
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 36
- 238000012123 point-of-care testing Methods 0.000 description 32
- 208000024891 symptom Diseases 0.000 description 30
- 238000011282 treatment Methods 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- 229940088710 antibiotic agent Drugs 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 16
- 239000012528 membrane Substances 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 210000002421 cell wall Anatomy 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 238000003066 decision tree Methods 0.000 description 11
- 231100000676 disease causative agent Toxicity 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000000020 Nitrocellulose Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 229920001220 nitrocellulos Polymers 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000012125 lateral flow test Methods 0.000 description 5
- 229960000282 metronidazole Drugs 0.000 description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 5
- 230000036963 noncompetitive effect Effects 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002967 competitive immunoassay Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960002100 cefepime Drugs 0.000 description 3
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 3
- 229960000484 ceftazidime Drugs 0.000 description 3
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960004659 ticarcillin Drugs 0.000 description 3
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 3
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 2
- 101710082714 Exotoxin A Proteins 0.000 description 2
- 206010061138 Fungal peritonitis Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 102000019298 Lipocalin Human genes 0.000 description 2
- 108050006654 Lipocalin Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000589774 Pseudomonas sp. Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- -1 carbapenems Chemical compound 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940090805 clavulanate Drugs 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002770 ertapenem Drugs 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102100024092 Aldo-keto reductase family 1 member C4 Human genes 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102100031515 D-ribitol-5-phosphate cytidylyltransferase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 1
- 101000994204 Homo sapiens D-ribitol-5-phosphate cytidylyltransferase Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101000922017 Mus musculus Cysteine and glycine-rich protein 1 Proteins 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 102000051143 human CRP Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940052337 quinupristin/dalfopristin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5421—IL-8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Definitions
- the application relates generally to medical devices, and more particularly to a diagnostic system, apparatus, and associated methods useful for, among other things, diagnosing and treating a peritoneal dialysis patient for peritonitis.
- Peritonitis is a major cause of morbidity and mortality in peritoneal dialysis (“PD”) patients globally.
- peritonitis can be diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, e.g., abdominal pain and/or cloudy dialysis effluent (“CDE”); (2) dialysis effluent with a white blood cell count (“WBC”) greater than 100/ ⁇ L or greater than 0.1 ⁇ 10 9 /L (after a dwell time of at least two hours), with more than 50% of the WBCs being polymorphonuclear (“PMN”); and (3) a positive peritoneal dialysis effluent (“PDE”) culture.
- CDE abdominal pain and/or cloudy dialysis effluent
- WBC white blood cell count
- PMN polymorphonuclear
- PDE positive peritoneal dialysis effluent
- Such therapy typically includes administering at least two different broad spectrum antibiotics which collectively cover most of the gram-positive and gram-negative bacteria, along with an anti-fungal agent to prevent secondary fungal peritonitis until the causative agent(s) and drug susceptibility tests become available.
- a product from Mologic Ltd. detects certain inflammatory markers, such as IL-6 and MMP8, in peritoneal dialysis effluent to alert peritoneal dialysis patients of inflammation and encourage further investigation.
- the product does not specifically identify the causative agent(s) of infection, which would assist in, e.g., prescribing antibiotics.
- inflammation may be present in some cases where there is no infection, such as inflammation caused by chemical irritants, mechanical injury to the peritoneum, or other conditions. In such cases, inflammatory status alone does not provide sufficient information for a clinician to make a timely and specific decision about treatment.
- WO2018/060708 describes a method of chemically detecting leukocytes (e.g., using redox indicators), and optionally simultaneously discriminating between gram-positive and gram-negative bacteria in peritoneal dialysis effluent.
- the described method is not specific for causative agent(s) of infection, and requires incubation times of at least two hours, and more typically 12 hours or more.
- Another limitation of the method is that it may not distinguish between Gram negative infections and infection with both Gram positive and Gram negative bacteria.
- Other devices may be useful to determine gram status of bacteria in bodily fluids, but they cannot simultaneously detect inflammation, and/or they cannot indicate specific bacterial species known that may be associated with peritonitis.
- a turbidity check of peritoneal dialysis effluent is another technology used by the Renal Research Institute (“RRI”) and liberDi. Ronco C, Dell'Aquila R, Rodighiero M P (eds): “Peritoneal Dialysis: A Clinical Update,” Contrib. Nephrol., Basel, Karger, 2006, vol. 150, pp 187-194.
- the principle is to predict peritonitis by evaluating the WBC count based upon turbidity.
- WBC count based upon turbidity.
- the sensitivity of a turbidity-based WBC test may be inadequate for use with many continuous ambulatory peritoneal dialysis (“CAPD”) patients.
- Yet another technology from DxNow is a portable bio-imaging system with microfluidic-based consumables for prediction of peritonitis.
- the principle is to capture WBCs in peritoneal dialysis effluent using WBC-specific antibodies and then conducting a count.
- This technology is intended to provide an accurate WBC count in a short time, however, it does not provide any information regarding causative agents and the device is sophisticated and relatively expensive.
- the described system can be used to perform, from the perspective of the user, a single test with easy sample pre-treatment.
- an assay for diagnosing an infection in a subject which assay includes a first binding molecule that specifically binds an inflammatory marker in a sample taken from the subject, and a second binding molecule that binds a marker indicative of the presence of a pathogen in the sample.
- the first binding molecule and the second binding molecule may be present on one test device or test strip.
- an assay kit that includes a binding molecule that specifically binds an antigen indicative of an inflammatory response in the peritoneum; a binding molecule that specifically binds an antigen indicative of the presence of gram-positive bacteria; and a binding molecule that specifically binds an antigen indicative of the presence of gram-negative bacteria.
- Such an assay kit may further include a binding molecule that specifically binds an antigen indicative of the presence of a fungus.
- the assay kit may further include a secondary binding molecule or molecules capable of binding to the indicated binding molecules.
- the secondary binding molecules may be conjugated to a reporter or indicator, such as a fluorescent reporter or other colorable reporter, nanoparticle, reactive particle such as an enzyme, or other reporter or indicator.
- the binding molecules and secondary binding molecules may be, for example, antibodies.
- the antigen indicative of an inflammatory response in the peritoneum is neutrophil gelatinase-associated lipocalin (“NGAL”), interleukin 1 (“IL-1”), interleukin 6 (“IL-6”), interleukin 8 (“IL-8”), tumor necrosis factor a (“TNF ⁇ ”), procalcitonin, and/or C-reactive protein (“CRP”).
- NGAL neutrophil gelatinase-associated lipocalin
- IL-1 interleukin 1
- IL-6 interleukin 6
- IL-8 interleukin 8
- TNF ⁇ tumor necrosis factor a
- procalcitonin and/or C-reactive protein (“CRP”).
- C-reactive protein C-reactive protein
- LTA Lipoteichoic acid
- LPS Lipopolysaccharide
- ⁇ -glucan is an antigen indicative of the presence of a fungus.
- the pathogen will typically be at least one bacterium and/or fungus.
- the assay/assay kit will include a binding molecule that specifically binds an antigen indicative of the presence of a specific pathogen species.
- the specific pathogen will typically be Staphylococcus aureus, Pseudomonas sp., Staphylococcus epidermidis, Staphylococcus haemolyticus, Candida sp., Escherichia coli, vancomycin-resistant enterococci, and combinations thereof.
- a lateral flow device comprises one or more panels to detect one or more antigens.
- multiple lateral flow devices can be integrated together to detect multiple antigens.
- Each lateral flow device comprising one or more panels may share a single sample reservoir.
- multiple lateral flow devices can be kept in the same housing but separated to detect antigens by use of individual panels.
- a single lateral flow device can be built in a multiplex format to detect multiple antigens using a single panel.
- the described assay(s)/assay kit(s) may further include means for filtering (e.g., a filter), concentrating (e.g., centrifugation), lysing cells, and/or enriching antigen(s) from the PDE.
- means for filtering e.g., a filter
- concentrating e.g., centrifugation
- lysing cells e.g., lysing cells
- enriching antigen(s) from the PDE e.g., a filter
- Sensitivity may be enhanced by concentrating the PDE, particularly for gram-positive and gram-negative antigens/markers.
- a syringe is used to filter and concentrate the PDE rather than a centrifuge.
- the described assay(s)/assay kit(s) may further include a buffer that specifically elutes antigen(s) from the assay kit.
- the buffer composition may be chosen to selectively stabilize the antigen and/or antigen-antibody complex, maintain pH, maintain or disrupt structure or binding of the antigen-antibody complex.
- a method of diagnosing peritonitis in a subject who is a peritoneal dialysis patient includes detecting in a peritoneal dialysis effluent (“PDE”) from the subject an antigen indicative of an inflammatory response having been launched in the peritoneum; detecting (e.g., utilizing appropriate binding molecule(s)) in the PDE an antigen indicative of the presence of gram-positive bacteria; and detecting (e.g., utilizing appropriate binding molecule(s)) in the PDE an antigen indicative of the presence of gram-negative bacteria.
- PDE peritoneal dialysis effluent
- results are provided in less than an hour.
- the method further includes detecting (e.g., by utilizing appropriate binding molecule(s)) in the peritoneal dialysis effluent an antigen indicative of the presence of a fungus.
- the method further includes filtering, concentrating, and/or enriching the peritoneal dialysis effluent prior to detecting antigen(s).
- enrichment may be by, for example, placing 50 ml of PDE into a conical tube, followed by centrifugation of the PDE sample, and treatment with, e.g., a lysis buffer, extraction buffer, and neutralization buffer.
- Enrichment of a PDE sample for antigens may also be by use of an ultrafiltration (“UF”) membrane (e.g., molecular weight cutoff 29,000).
- UF ultrafiltration
- a syringe is used to pass/push the PDE through a UF membrane instead of a centrifuge.
- Such diagnostic methods can be used to treat peritonitis in the subject by first diagnosing the subject as having peritonitis and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the diagnosis.
- a paper device that utilizes lateral flow assay technology and/or dry chemistry test technology is disclosed to simultaneously detect the presence of cell wall components and/or surface antigen(s) from contaminating microorganisms and/or inflammatory biomarkers in a patient's PDE.
- lateral flow technology and/or dry chemistry test technology is used to rapidly assist clinicians in diagnosing an infection in the peritoneal dialysis patient when the patient presents in the clinic with cloudy peritoneal dialysis effluent and/or other symptoms of peritonitis.
- detection is based upon a lateral flow test (also known as a lateral flow immunochromatographic assay), which is a simple, paper-based device used to detect the presence of a target analyte in a liquid sample without the need for specialized and costly equipment.
- the device aids in the determination of the contaminating microorganism(s) so that, for example, appropriate antibiotics therapy can be promptly prescribed.
- the device and associated methods for using it assist clinicians (and patients and caregivers) in quickly determining the existence of an infection in a peritoneal dialysis patient and aid in providing treatment therefore so as to improve the management of peritoneal dialysis-related peritonitis.
- a goal is to thus rapidly and simultaneously detect the presence of multiple molecular markers that are released from the patient's host immune system and/or pathogens as soon as the invasion of pathogens is thought to have occurred in the patient.
- FIGS. 1 through 5 and 7 depict various embodiments of lateral flow devices as described herein.
- FIG. 6 is a flow diagram of a process according to the disclosure.
- FIG. 8 is a flow diagram of a “test results driven approach.”
- FIG. 9 is a flow diagram of a “symptoms driven approach.”
- a “binding molecule,” e.g., an antibody (monoclonal or polyclonal) or antigen-binding fragment thereof, aptamer, affimer (peptide aptamer), receptor binding domain, or designed ankyrin repeat proteins (DARPins) is a molecule that specifically binds an antigen.
- the term “antigen-binding fragments” means a portion of an intact binding molecule, such as an antibody.
- antibody fragments include Fab, Fab′, F(ab′)2 and Fv fragments, CDR, antigen-binding site, heavy or light chain variable region, diabodies, triabodies single chain antibody molecules (“scFv”) and multi-specific antibodies formed from at least two intact antibodies or fragments thereof or peptides or polypeptides that contain at least a fragment of an immunoglobin that is sufficient to confer antigen binding to the peptide or polypeptide, etc.
- scFv single chain antibody molecules
- An antigen-binding fragment may comprise a peptide or polypeptide comprising an amino acid sequence of at least 2, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, or 250 contiguous amino acid residues of the amino acid sequence of the antibody.
- the antigen-binding fragments may be produced synthetically or by enzymatic or chemical cleavage of intact immunoglobulins or they may be genetically engineered by recombinant DNA techniques. The methods of production are well known in the art and are described, for example, in Antibodies: A Laboratory Manual, edited by: E. Harlow and D, Lane (1988), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- An antibody or antigen-binding fragment thereof has one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different.
- the term “specifically binding,” or “specifically recognize,” as used herein, in reference to the interaction of an antibody and its binding partner, e.g., an antigen, means that the interaction is dependent upon the presence of a particular amino acid sequence or structure, e.g., an antigenic determinant or epitope, on the binding partner. In other words, the antibody preferentially binds or recognizes the binding partner even when the binding partner is present in a mixture of other molecules or organisms.
- the binding may be mediated by covalent or noncovalent interactions or a combination of both.
- the term “specifically binding” or “specifically recognizes” means that the antibody is specifically immunoreactive with an antigenic determinant or epitope and is not immunoreactive with other antigenic determinants or epitopes.
- An antibody that specifically or immunospecifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., radioimmunoassays (“RIA”), enzyme-linked immunosorbent assays (“ELISA”), BIACORE, or other assays known in the art.
- Antibodies or fragments thereof that specifically bind to an antigen may be cross-reactive with related antigens, carrying the same epitope.
- antibodies or fragments thereof that specifically bind to an antigen do not cross-react with other antigens.
- the device is configured to detect one, two, or more inflammatory markers such as, e.g., neutrophil gelatinase-associated lipocalin (“NGAL”) and interleukin 6 (“IL-6”), as well as one, two, three, or more cell wall components, such as lipoteichoic acid (“LTA”), lipopolysaccharide (“LPS”), and ⁇ -glucan in one device.
- NGAL neutrophil gelatinase-associated lipocalin
- IL-6 interleukin 6
- LTA lipoteichoic acid
- LPS lipopolysaccharide
- ⁇ -glucan ⁇ -glucan
- NGAL neutrophil lipocalin
- lipocalin 2 lipocalin 2, siderocalin, or neutrophil lipocalin
- neutrophil lipocalin is a 25 kDa glycosylated single chain monomer and member of the lipocalin family of proteins that bind and transport small lipophilic molecules.
- NGAL is released by activated neutrophils, as well as renal tubule epithelial cells, cardiomyocytes, uterus, prostate, salivary glands, and other tissues, and can be found in both serum and urine.
- NGAL can form dimers, forming a 45 kDa disulfide-linked homodimer, small amounts of higher oligomers, and a 135 kDa heterodimer with matrix metalloproteinase 9 (“MMP-9,” gelatinase B).
- MMP-9 matrix metalloproteinase 9
- NGAL is involved in innate immunity.
- the homodimer form is specifically released by neutrophils that infiltrate into the peritoneum immediately after the invasion of a pathogen, while the monomer and heterodimer are more generally released by tubular cells and the other indicated tissues in response, for example, to acute kidney injury.
- NGAL peritoneal dialysis effluent
- Antibodies that specifically bind NGAL are readily commercially available.
- a goat IgG polyclonal antibody is available under Catalog #PAS-18382 from ThermoFisher Scientific.
- Anti-NGAL antibody (ab63929, rabbit polyclonal to NGAL), is available from Abcam (Cambridge, Mass., US).
- Interleukin 6 is expressed and secreted by mesothelial cells, which serve as the first layer of the host defense system of the peritoneum. Once pathogens invade, the mesothelial cells upregulate expression of IL-6, and a higher level of IL-6 is thus detectable in the peritoneal dialysis effluent. IL-6 levels rapidly increase in the drained PDE before the onset of peritonitis, during peritonitis, and even after peritonitis.
- Antibodies that specifically bind IL-6 are readily commercially available.
- monoclonal antibodies MAB2061-SP, MAB2061-100, and MAB2061-500 are human IL-6 antibodies that bind human IL-6 in direct ELISAs, but do not cross-react with recombinant IL-6 from mouse, rat, or pig.
- Anti-IL-6 antibody (ab6672, rabbit polyclonal to IL-6), is available from Abcam (Cambridge, Mass., US).
- IL-6 is however commonly detected in peritoneal dialysis patients (even without infection) due to the continuous irritation that may be caused by the peritoneal dialysis fluid. Therefore, the threshold of IL-6 detection limit is preferably adjusted in the device to more reliably indicate the existence of an infection. In this regard, IL-6 may not be the best marker to use, or may be better to use in combination with other inflammatory markers.
- IL-6 is replaced with a different inflammatory marker, such as procalcitonin or C-reactive protein (“CRP”). Both of these inflammatory markers are useful in the prediction of peritonitis.
- a different inflammatory marker such as procalcitonin or C-reactive protein (“CRP”). Both of these inflammatory markers are useful in the prediction of peritonitis.
- inflammatory markers include TNF ⁇ , fibrinogen, MPO, HAS, fMLP, A1AT, TIMP2, TIMP1, sICAM, MMP 9, HNE, cystatin C, IL-lb, IL-8, calprotectin, RBP4, MMP 8, MMP 2, desmosine, and SPD.
- Monoclonal antibodies against TNF ⁇ include infliximab (REMICADETM), adalimumab (HUMIRATM), certolizumab pegol (CIMZIATM), and golimumab (SIMPONITM).
- REMICADETM infliximab
- HUMIRATM adalimumab
- CCMZIATM certolizumab pegol
- SIMPONITM golimumab
- Antibodies that specifically bind fibrinogen are readily commercially available.
- anti-fibrinogen antibody (ab189490, rabbit monoclonal to fibrinogen) is available from abcam (Cambridge, Mass., US).
- a polyclonal sheep anti-Human Fibrinogen antibody is available under Catalog #AF4786 from R&D Systems. This antibody detects human fibrinogen in direct ELISAs and Western blots.
- Antibodies that specifically bind procalcitonin are readily commercially available.
- anti-procalcitonin antibody (ab166963, sheep polyclonal to procalcitonin) is available from Abcam (Cambridge, Mass., US).
- a mouse procalcitonin monoclonal antibody (27A3) is available under Catalog #MA1-20887 from ThermoFisher Scientific.
- MA1-20887 detects procalcitonin in human samples and has been successfully used in ELISA and Western blot procedures.
- the MA1-20887 immunogen is an internal fragment of purified, full length, native human calcitonin.
- CRP C-reactive protein
- anti-C Reactive Protein antibody ab31156, rabbit polyclonal to human CRP
- Abcam Abbridge, Mass., US
- a mouse CRP monoclonal antibody P4D7 is available under Catalog #MIC0501 from Invitrogen Antibodies/ThermoFisher Scientific.
- NGAL and IL-6 in the peritoneal dialysis effluent indicate both the activation of innate immunity and that there is a host defense in the peritoneum, which are initiated at the beginning of peritonitis.
- the device could also use only a gram-positive inflammatory marker(s) with an additional technology.
- turbidity detection technology e.g., that of RRI
- a binding molecule that binds a marker indicative of the presence of a pathogen could obviate the use of a binding molecule for an inflammatory marker.
- a method of treating peritonitis in a subject who is a peritoneal dialysis patient comprising: first determining if turbidity is present in a peritoneal dialysis effluent, analyzing the subject's peritoneal dialysis effluent to determine the identity of an infectious microorganism (e.g., Gram (+), Gram ( ⁇ ) and/or fungal infection), and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the determination of the identity of the microorganism.
- an infectious microorganism e.g., Gram (+), Gram ( ⁇ ) and/or fungal infection
- turbidity detection may be used in combination with a binding molecule that binds a marker indicative of the presence of a pathogen and a binding molecule that binds an inflammatory marker.
- a binding molecule that binds a marker indicative of the presence of a pathogen and a binding molecule that binds an inflammatory marker.
- Such a combination of indicators can provide additional benefits to the patient or clinician, particularly in early diagnosis of infection and early characterization of specific agents of infection.
- Peptidoglycan is a key component of the cell wall of bacteria and thus serves as a reliable marker of bacterial infection, distinguishing other causes of inflammation and/or infection.
- Lipoteichoic acid is a glycerol phosphate surface polymer component of the envelope of Gram ⁇ positive bacteria. LTA is anchored via its glycolipids to the membrane and carries a polysaccharide chain extending into the peptidoglycan layer of the cell wall. LTA is released spontaneously into the culture medium during growth of gram-positive bacteria. LTA functions as an immune activator with characteristics very similar to lipopolysaccharide (LPS) from Gram ⁇ negative bacteria. LTA binds to CD14 and triggers activation predominantly via Toll-like receptor 2. Although LTA is internalized and traffics to the Golgi, cellular activation in response to LTA occurs at the cell surface.
- LPS lipopolysaccharide
- Antibodies that specifically bind to LTA are readily commercially available.
- a mouse monoclonal antibody is available under Catalog #MA1-40134 from ThermoFisher Scientific.
- MA1-40134 detects LTA from gram-positive bacterial samples, and has been successfully used in Western blot, ELISA, flow cytometry, immunofluorescence, and immunohistochemistry (frozen) applications.
- Another mouse monoclonal antibody (IgG3) is available under Catalog #GWB-9E3242 from Genway Biotech, Inc. (San Diego, Calif., US).
- mouse monoclonal LTA antibodies are available, for example, under Catalog #LS-C102921, LS-C102920, LS-C202488, and LS-C757317 from LifeSpan Biosciences, Inc. (Seattle, Wash., US).
- LPS is a cell wall component of gram-negative bacteria.
- Antibodies that specifically bind LPS are readily commercially available.
- a rabbit polyclonal antibody preparation is available under Product No. PAB526Ge01 from Cloud-Clone Corp. that has the ability to recognize LPS in immunohistochemical staining and western blotting.
- a lipopolysaccharide (LPS) mouse monoclonal antibody is available under Catalog No. CAU29364 from Biomatik (Cambridge, Ontario, CA).
- ⁇ -glucan is a cell wall component of fungi.
- Antibodies that specifically bind ⁇ -glucan are readily commercially available. See, also, U.S. Pat. No. 7,893,219 to Cassone et al. (Feb. 22, 2011), the contents of which are incorporated herein by this reference.
- LTA, LPS, and ⁇ -glucan are cell wall components of gram-positive bacteria, gram-negative bacteria, and fungi, respectively.
- the presence of such cell wall component(s) in the patient's peritoneal dialysis effluent is indicative both that infection is occurring and the specific type of causative agent(s).
- other specific antigens can be detected to indicate the presence of the specific pathogen (e.g., bacteria) species in the peritoneal dialysis effluent.
- specific pathogens e.g., bacteria
- specific pathogens are selected from the group consisting of Staphylococcus aureus, Pseudomonas spec., Staphylococcus epidermidis, Staphylococcus haemolyticus, vancomycin-resistant enterococci, Candida sp., Escherichia coli, and mixtures thereof.
- lysostaphin could be used to detect Staphylococcus aureus and exotoxin A could be used to detect Pseudomonas spec.
- Monoclonal and polyclonal anti-lysostaphin antibodies are commercially available from Antibody Research Corporation (St. Peters, Mo., US) under the SKUs 111145 and 111135, respectively.
- Polyclonal anti- Pseudomonas Exotoxin A antibodies produced in rabbit are available from Sigma-Aldrich/Millipore SiGMa under the MDL number MFCD00162779.
- Staph. aureus -specific peptidoglycan can be used to specifically detect Staph. aureus in PDE.
- Monoclonal antibodies are available from QED Biosciences, Inc. (San Diego, Calif., US) under the Catalog Nos. 15702, 15703, and 15704; from Meridian Life Science, Inc. (Memphis, Tenn. US) under the Catalog No. C55570M, and from Abcam, Inc. (Cambridge, Mass., US) under the Product name ab37644.
- These antibodies recognize peptidoglycan of Staph. aureus, Protein A-negative Staph. aureus, and Staph. epidermidis.
- Single agent antibiotics for treating peritonitis include ertapenem (INVANZTM), cefoxitin, doripenem (DORIBAXTM), imipenem/cilastatin (PRIMAXINTM), ertapenem, imipenem/cilastatin, meropenem (MERREMTM), moxifloxacin (AVELOXTM), piperacillin/tazobactam (ZOSYNTM), ticarcillin/clavulanate, piperacillin/tazobactam, ticarcillin/clavulanate (TIMENTINTM), and tigecycline (TYGACILTM).
- Combination therapy antibiotics include cefepime (MAXIPIMETM), cefotaxime (CLAFORANTM), ceftazidime (FORTAZTM), or ceftriaxone (ROCEPHINTM), together with metronidazole (FLAGYLTM). Or cefazolin, cefotaxime, ceftriaxone, ciprofloxacin (CIPROTM), levofloxacin (LEVAQUINTM), together with metronidazole. Or cefepime, ceftazidime, ciprofloxacin, levofloxacin, together with metronidazole. Or gentamicin or tobramycin together with clindamycin (CLEOCINTM) or metronidazole (with or without ampicillin). Such antibiotics are typically administered per established protocols.
- Antibiotic treatment against Pseudomonas sp. typically involves administration of one or more of the following antibiotics: ceftazidime, ciprofloxacin or levofloxacin, gentamicin, cefepime, aztreonam, carbapenems, ticarcillin, and/or ureido penicillins.
- Penicillinase-resistant penicillins are antibiotics for treating serious methicillin-susceptible S. aureus (“MSSA”) infections, but first generation cephalosporins (cefazolin, cephalothin and cephalexin), clindamycin, lincomycin and erythromycin are used in less serious MSSA infections or in patients with penicillin hypersensitivity. All serious MRSA infections should be treated with parenteral vancomycin or teicoplanin. Nosocomial strains of MRSA are typically multi-resistant (“mrMRSA”); mrMRSA strains may be treated with a combination of two oral antimicrobials, such as rifampicin and fusidic acid.
- Lincosamides (clindamycin, lincomycin) or cotrimoxazole may be used to treat less serious MRSA infections.
- Antibiotics such as linezolid and quinupristin/dalfopristin have anti-staphylococcal activity.
- LFA lateral flow assay
- LFT lateral flow test
- LFD lateral flow device
- LFIA lateral flow immunoassay
- DIPA lateral flow immunochromatographic assays
- Lateral flow assays typically have a control line to confirm that the test is working properly, along with one or more target or test lines. They are designed to incorporate intuitive user protocols and require minimal training to operate. They can be qualitative and read visually, or quantitative when combined with reader technology, such as ADxLR5®.
- Lateral flow tests are widely used in human health for point-of-care testing. They can be performed by a healthcare professional or by the patient, and in a range of settings including the laboratory, clinic, or home.
- Lateral flow assays can be developed to be used in a dipstick format or in a housed cassette. Both dipsticks and housed tests will work in a similar way, dependent on the industry, sample matrix, and the market requirement.
- non-competitive assays could be adapted for use herein (e.g., by utilization of an enrichment method such as centrifugation to increase the sensitivity of detection), sandwich (or “non-competitive”) assays are typically preferred for use herein.
- sandwich (or “non-competitive”) assays are typically preferred for use herein.
- a non-competitive immunoassay format a positive test is typically represented by the presence of a colored line at the test line position.
- a non-competitive immunoassay format is ideal for large molecular weight analytes with multiple antigenic sites.
- non-competitive immunoassays have a lower limit of detection (heightened analytical sensitivity) compared to a competitive format.
- non-competitive immunoassays can detect on the order of picograms/mL (parts per trillion) in comparison to nanograms/mL (parts per billion) for the competitive assay format.
- Lateral flow devices typically utilize immunoassay technology with a nitrocellulose membrane, colored latex nanoparticles (or labels such as magnetic beads or colored styrene balls), and antibodies, for quick analysis (see, e.g., FIG. 1 ).
- the sample flows along the test device passing through a conjugate pad into a nitrocellulose membrane and then onto an absorbent pad to absorb excess sample.
- the sample pad acts as the first stage of the absorption process, and in some cases contains a filter to ensure the accurate and controlled flow of the sample.
- the conjugate pad which stores the conjugated labels and antibodies, receives the sample. If the target is present, the immobilized conjugated antibodies and labels bind to the target and continue to migrate along the test.
- the binding reagents situated on the nitrocellulose membrane bind to the target at the test line.
- a colored line forms and the density of the line varies depending on the quantity of the target present. Some targets may require quantification to determine the target concentration such as by using a reader.
- Conjugate labels used with lateral flow devices include: colloidal gold, cellulose nanobeads, fluorescent latex, paramagnetic particles, up-converting phosphors, and various fluorescent labels.
- the cell wall components are detected by dry chemistry if, for example, the specificity of the antibodies in the lateral flow test is inadequate. Dry chemistry is based upon specific recognition of cell wall component(s) by, e.g., enzymes.
- a more sophisticated system can be used to acquire quantitative data instead of qualitative data.
- the immunofluorescence technology together with a reader may be utilized to measure the quantity of markers in peritoneal dialysis effluent to provide more information to the patients and clinicians by comparing the obtained values with a predetermined cutoff value.
- each biomarker or cell wall component is preferably carried out in an individual channel, although all detections are made simultaneously by using the same peritoneal dialysis effluent sample.
- Such a design can prevent cross-reaction between biomarkers or cell wall component(s).
- peritoneal dialysis effluent sample it is preferred to add peritoneal dialysis effluent sample to each channel. But alternatively, more than one channel can be connected to each other to avoid repeatedly adding the peritoneal dialysis effluent sample. Accordingly, described is a point-of-care device and assay for testing for peritonitis in dialysis effluent, especially in peritoneal dialysis effluent, providing several advantages over conventional assays and improving peritonitis management.
- the device and methods are inexpensive, rapid, and easy to use by a patient or clinician with only limited training.
- an optimal treatment regimen e.g., specific antibiotic therapy or mixed therapy
- a particular advantage is that the disclosed device and assay combines both inflammatory marker testing and specific infection agent testing in a single, inexpensive, and simple to use device.
- the device and assay gives the patient and clinician substantially more information about actual infection and appropriate peritonitis management than previous technology. For example, tests looking only at inflammatory status rely exclusively on non-specific markers of infection. Even if the test is positive for one or more inflammatory markers (alone), the clinician does not gain significant information about which specific type of therapy (e.g., specific type of antibiotic) to prescribe.
- specific type of therapy e.g., specific type of antibiotic
- the disclosed assay adds an agent-specific test (e.g., Gram status, specific bacterium, fungus, etc.) to the inflammatory marker, greatly increasing reliability of the diagnosis of pathogen-associated peritonitis, while reducing the time needed to implement the most appropriate therapy.
- agent-specific test e.g., Gram status, specific bacterium, fungus, etc.
- PDE samples according to the disclosed assay and device do not necessarily require pre-treatment or any special processing before they are applied to the device, so patients can perform the entire test in their homes immediately.
- the clinician can quickly prescribe a targeted antibiotic that is most suitable for treating a known Gram positive or Gram negative bacterial infection.
- the combined device is also cheaper and easier to use and interpret than two devices or multiple assays, and results can be read in less than 10 minutes in most cases.
- a patient in a home setting could accordingly test their own PDE, identify a specific positive result and report to their clinician, and be directed to begin a course of targeted treatment immediately. Such therapy could be initiated even where other classical signs of infection (e.g., pain, fever, cloudy effluent) are not yet present.
- other classical signs of infection e.g., pain, fever, cloudy effluent
- the severity and duration of peritonitis in, for example, PD patients may be reduced, allowing them to stay on PD longer without the need for more invasive forms of dialysis, such as hemodialysis.
- improper antibiotics i.e., empiric, broad-spectrum antibiotics where a more targeted therapy is indicated
- a picture is taken of the results of the test, which are transmitted to a health care practitioner.
- a mobile telephone “app” is used to analyze the results, and provide the patient with a notation to, for example, “Call your health care provider” or “Peritonitis Confirmed.”
- this can further include analysis of a picture of the analyte, using technology as described in International Application No.: PCT/EP2017/000803 (International Publication No. WO 2018/007013 published on Jan. 11, 2018), the contents of which are incorporated herein by this reference.
- FIGS. 1 through 5 and 7 illustrate various embodiments of a lateral flow device according to the invention.
- the device is configured to detect NGAL, LTA, ⁇ -glucan, LPS, and IL-6 in one test.
- a volume of analyte (e.g., PDE) is deposited into a well portion of the strip.
- the PDE flows away from the well (e.g., by capillary action), down the strip, and interacts with a conjugate of appropriate labeled antibodies associated with the strip.
- Other antibodies having the same specificity as the labeled antibodies are affixed to the strip (at the solid phase).
- the appropriate antigen e.g., NGAL, LTA, ⁇ -glucan, LPS, or IL-6
- it will bind with the labeled antibodies and form a sandwich complex at the portion of the strip where the solid phase antibodies are present, and the sandwich complex will be detectable.
- a control line is further depicted to ensure the POCT is performing properly. Excess reagent passes to the end of the strip.
- FIGS. 2 and 3 represent various configurations of a lateral flow device according to the disclosure (and FIG. 1 ), including four sample wells and four roughly-parallel and adjacent channels configured to detect LTA, LPS, NGAL, and IL-6.
- This embodiment has the advantage of taking up relatively little space, while requiring application of four relatively low-volume PDE samples to utilize all four channels.
- the control lines are distal from the wells and test lines closer to the wells.
- FIGS. 4 and 5 represent an alternative configuration of a lateral flow device of the disclosure, including a single, central sample well and four channels that radiate away from the central well, configured again to detect LTA, LPS, NGAL, and IL-6.
- This embodiment has the advantage of requiring only one sample of PDE to be applied by the patient or clinician.
- FIGS. 2 and 4 also indicate possible dimensions (in millimeters) for the lateral flow device and ranges for such dimensions, according to certain embodiments.
- the device depicted in FIG. 2 can have a width 38 with a Range of 30 ⁇ 60 mm and a Tolerance of ⁇ 1 ⁇ +1, a height 70 having a Range of 55 ⁇ 100 mm and a Tolerance of ⁇ 1 ⁇ +1, depicted distance 60 having a Range of 50 ⁇ 80 mm and a Tolerance of ⁇ 1 ⁇ +1, and depicted width 4 of the channel having a Range of 2.5 ⁇ 8 mm and a Tolerance of ⁇ 1 ⁇ +1.
- a height and width 90 with a Range of 70 ⁇ 120 mm and a Tolerance of ⁇ 1 ⁇ +1, depicted distance 60 having a Range of 50 ⁇ 80 mm and a Tolerance of ⁇ 1 ⁇ +1, and depicted width of the channel having a Range of 2.5 ⁇ 8 mm and a Tolerance of ⁇ 1 ⁇ +1.
- FIG. 7 illustrates a triple-chevron configuration (e.g., FRESENIUSTM logo), to which sample is applied to the center of each chevron. The sample then flows laterally or longitudinally along multiple channels to test lines where appropriate and binding reagents bind antigens that may be present in the samples.
- a triple-chevron configuration e.g., FRESENIUSTM logo
- results of all analytes at the same time point, for instance, after 15-30 minutes.
- the results can be read consecutively.
- the described samples are peritoneal dialysis effluents.
- the peritoneal dialysis effluent is used directly after draining to detect one or more markers of infection.
- the peritoneal dialysis effluent is first concentrated and/or filtered, and subsequently used to detect one or more markers of infection.
- the shape of the device has no limit so long as the individual channels are maintained.
- Methods In certain embodiments, after a patient has presented in the clinic with a cloudy peritoneal dialysis effluent and/or other symptoms of infection, the practitioner can quickly use the device before sending samples for WBC count and culture. The practitioner can then interpret the results and provide to the nephrologist or supervisor the test results, symptoms, history, etc., along with a possible antibiotics prescription(s).
- the device can be used at home by patients.
- the patient should inform the clinician(s) of the results immediately and follow the suggested instructions for treatment, e.g., orally taken antibiotics, or adding antibiotics directly into fresh dialysis solution for the next exchange. This may happen, for example, outside of clinic hours or for those patients who live in a rural area, without having to wait to present at clinic before implementing a necessary therapeutic regimen.
- the device can be used by clinician(s) or the patient to determine whether the prescribed treatment has been effective.
- the device is utilized as part of an integrated care management protocol.
- results determined by the device are processed by one or more portable electronic devices (e.g., smartphone app, computer, tablet, etc.) and may be associated with a digital application.
- the results may in turn be integrated via a cloud or network-based communication path to a remote clinician, laboratory, or other health professional for further evaluation and instruction.
- a remote professional may then direct appropriate clinical action by the patient or on-site professional, such as directing immediate administration of an appropriate antibiotic or other therapy, direct the patient to come to the clinic, or otherwise indicate appropriate care.
- a remote professional can send an electronic code to open a medicine lockbox, for example, in the patient's home, with the appropriate medication.
- one or more clinical protocols i.e., “decision trees” utilizing the described device and/or method are disclosed.
- Such protocols may be a “test results driven approach” ( FIG. 8 ) as, for example, initiated in response to an observable indicator of infection such as turbidity, or may be “symptom driven” ( FIG. 9 ) as for example may be initiated by a patient symptom such as pain or fever.
- the “Test results driven approach” of FIG. 8 is applicable to scenarios when turbidity is captured automatically on each treatment, or when the patient undergoes a turbidity test manually after his or her dialysis treatment. As depicted in FIG. 8 , if Turbidity is positive (“Turbidity+” 20 ), then a Point of Care Test (“POCT”) as described herein is administered.
- Turbidity+ Turbidity+
- POCT Point of Care Test
- the results of the POCT are analyzed in an attempt to determine the etiology of the infection and appropriate follow up administered. For example, if the etiology of the infection is inconclusive 24 , then the patient is requested to seek clinical evaluation 26 . If the etiology of the infection is determined to be a Gram+ bacteria (“Gram+”), then an appropriate antibiotic 28 (or other acceptable treatment) is prescribed for the patient. If the etiology of the infection is determined to be a Gram negative bacteria (“Gram ⁇ ”), then an appropriate antibiotic 30 (or other acceptable treatment) is prescribed for the patient.
- Gram+ Gram+ bacteria
- Gram ⁇ Gram negative bacteria
- a patient should still proceed with a clinical evaluation to define the etiology of the turbidity (not shown).
- Turbidity negative (or inconclusive) 36 with Symptoms positive 38 even if the POCT is negative 40 , where the decision tree states “No further action*” 42 , a different etiology other than bacterial peritonitis should be considered and a clinical evaluation could be necessary.
- Turbidity is negative or inconclusive 36 and Symptoms are negative 54 , then generally, no further action is required 56 .
- the “symptoms driven approach” of FIG. 9 can be used, for instance, when turbidity is not captured automatically, or when the patient does not undergo a turbidity test after his or her treatment. Under such circumstances, when Symptoms are negative 58 , no further action is required 60 . However, when Symptoms are positive 62 and a Turbidity test results negative 64 , further clinical evaluation 66 is indicated.
- Symptoms are positive 62 and a Turbidity test is either positive or not conducted 68 , a POCT is preferably conducted.
- the treatment is as the Test results driven approach. For example, if the etiology of the infection is inconclusive 76 , then the patient is requested to seek clinical evaluation 78 . If the etiology of the infection is determined to be a Gram+bacteria (“Gram+”), then an appropriate antibiotic 80 (or other acceptable treatment) is prescribed for the patient. If the etiology of the infection is determined to be a Gram negative bacteria (“Gram ⁇ ”), then an appropriate antibiotic 82 (or other acceptable treatment) is prescribed for the patient.
- Gram+ Gram+bacteria
- Gram ⁇ Gram negative bacteria
- turbidity may be eliminated entirely as a required test, and the decision to implement POCT testing may be driven entirely by the presence or absence of symptoms. This may be the case where, for example, turbidity data is inconclusive or unreliable, or where the clinician or patient wants to expedite the POCT testing, as may be the case where the patient has a history of a specific type or types of peritonitis infections and the primary interest is in narrowing the most likely cause of infection quickly.
- the POCT is configured to detect the presence of, e.g., a fungal infection (not shown), and this tests positive, then an appropriate antifungal agent and/or therapy may be prescribed.
- FIGS. 1-3 The assay of FIGS. 1-3 is made with the following antibody components incorporated into a paper-based (e.g., nitrocellulose) LFD:
- Antibody list capture antibody, detector antibody (BSA gold conjugated), anti-biotin gold antibody.
- Three drops of PDE sample are placed onto the sample receiving portions of each of the wells of the device shown in FIG. 1 , fluid flows into each of the channels and moves by diffusion through the nitrocellulose paper to a capture zone containing a capture (i.e., primary) antibody, and from there continues to a detection zone within a detection window containing one or more detection (i.e., secondary) antibodies.
- Results are read visually or using an optical reader, mobile device, or similar to determine if the PDE sample is positive for one or more markers of infection and/or inflammation.
- Protocol Rapid PD-related peritonitis diagnosis at dialysis clinic or home (following the flow diagram of FIG. 6 ).
- a PD patient displays any sign of peritonitis (e.g., cloudy PDE, abdominal pain, and/or fever), he or she is to visit a dialysis clinic or doctor as soon as possible.
- the nurse or other health care professional drains the PD effluent into a waste bag and collects samples for routine testing such as cell count, gram stain, and culture.
- a PD patient may collect and test samples using the disclosed assay and device before going to a dialysis clinic or doctor. What follows is rapid testing of the same PDE sample before it is sent for routine testing (e.g., cell culture, Gram stain, cell count, etc.)
- a container for centrifugation 25 ml of PDE is placed into a container for centrifugation, which is separated into an upper chamber and a lower chamber by an ultrafiltration (“UF”) membrane having a molecular weight cutoff of 29,000.
- the container is capped and placed into a centrifuge and spun ( ⁇ 4000 g).
- the PDE is filtered through the UF membrane and pushed from the upper chamber to the lower chamber, creating an enriched PDE.
- a few drops of the enriched PDE are placed onto the sample port of the IL-6/NGAL panel of the device of EXAMPLE I, and any reaction is determined.
- the UF membrane is mixed with elution buffer, and a few drops are placed onto the sample port of the LPS/LTA panel of the device of EXAMPLE I, and any reaction determined.
- NGAL and IL-6 reference levels for each sample were determined with JiuQiang biochemistry NGAL test and the SIEMENS chemiluminescence IL-6 test.
- the assay had 4 strips corresponding to NGAL, IL-6, LTA, and LPS.
- NGAL and IL-6 were used as inflammatory indicators for peritonitis.
- LTA was used as an indicator of Gram positive bacterial infection.
- LPS was used as an indicator for Gram negative bacterial infection, with the following reagents associated with each of the relevant strips:
- Test results were visually read, with a negative result indicated if the control line was positive and test line was negative; and a positive result indicated if the control line and test line were positive. See FIGS. 1-3 .
- the combination of the NGAL 80 ng/ml & IL-6 200 pg/ml combination indicator presents the best sensitivity and specificity for these markers in peritonitis detection.
- the specificity for LTA was 96.6% and for LPS was 100%.
- CMCC(B) 26001 Staphylococcus aureus
- ATCC 12228 Staphylococcus epidermidis
- CMCC(B) 32210 beta hemolytic Streptococcus
- E. coli 0157:H7 ATCC35150
- Pseudomonas aeruginosa ATCC 27853
- NGAL80 ng/ml & IL-6 200 pg/ml presents 100% specificity with 19 PDEs from normal patients.
- LTA and LPS tests also presents 100% specificity with the 19 PDEs.
- Example V The results of Example V and Example IV were compiled to derive a composite sensitivity and specificity as shown in Tables E, F, and G.
- the assay showed a good ability to detect peritonitis in PDE samples, with specificity of 91.8% and sensitivity of 100%.
- the assay also indicated the specific type of pathogen of infection. The most frequent bacterial pathogens associated with peritonitis can be detected and distinguished as Gram negative or Gram positive.
- the assay/assay kit as described above is modified to include a binding molecule that specifically binds to an antigen indicative of the presence of a specific pathogen species, in this example, Staphylococcus aureus by substituting antibodies specific for S. aureus (e.g., ab37644 from Abcam, catalog number 15704 from QED Bioscience, Inc., or C55570M from Meridian Life Science, Inc.) for one of the antibodies used in the standard assay (i.e., specific for LTA, LPS, NGAL, IL-6, or ⁇ -glucan).
- an antibiotic therapy e.g., cotrimoxazole
- the assay/assay kit as described in FIGS. 1 and 2 [having four parallel lanes] was modified to include an antibody that specifically binds to the peptidoglycan antigen of Staphylococcus aureus (MA1-10708 and MA1-10709 from Invitrogen, Inc.), instead of the LTA-specific antibody.
- the decision tree/protocol is initiated by a turbidity test, which can be patient/practitioner initiated (as using a visual inspection or cell-phone based scan of the dialysis bag) or can be monitored using one or more sensors integrated with the dialysis bag or tubing.
- turbidity methods that may be suitable for use in the present disclosure may be found in PCT Publication WO2018/007013, filed Jul. 7, 2017 and titled “Method and Smartphone for Detecting Symptoms of Peritonitis,” the contents of which are incorporated herein by this reference.
- This decision tree can be initiated even in the absence of symptoms, permitting a possibly earlier detection of infection than is customarily seen in current practice.
- turbidity is positive 20
- samples of the PD effluent are applied to the disclosed device to evaluate Gram status.
- Appropriate antibiotic therapy can be rapidly initiated based on a Gram+ or Gram ⁇ result, or the patient can be directed to further evaluation by a clinician if Gram status is inconclusive.
- the POCT test is negative 32 with a positive turbidity test, the patient can be directed to take no further action (assuming symptoms are absent) or to seek further clinical evaluation 34 (e.g., depending on the breadth of the POCT in detecting, for instance, fungal infections).
- this decision tree is primarily symptom-driven and may be utilized for example in situations where turbidity is not captured automatically or where patients are not routinely performing turbidity tests after treatment.
- the presence of one or more symptoms 62 of infection would indicate that a turbidity test be taken. If turbidity is positive or not available 68 , the patient would then be directed to use the POCT device. If the POCT device reports either a Gram+ or Gram ⁇ bacterium is present, appropriate antibiotic therapy 80 , 82 can be immediately implemented. Where symptoms are present 62 , but turbidity is absent 64 , the patient may be directed to clinical evaluation 66 .
- the POCT device may recommend the patient to determine if a specific cause of infection is present.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Described is an assay for diagnosing an infection such as peritonitis in a subject. The assay includes a binding molecule, such as an antibody that specifically binds to an inflammatory marker in a sample from the subject, and a second binding molecule that binds to a marker indicative of a pathogen in the sample. For diagnosing peritonitis in a subject, the pathogen will be at least one bacterium and/or fungus. Typically, the assay will be incorporated into a lateral flow device and may include a binding molecule that specifically binds to an antigen indicative of the presence of a specific pathogen species. The described assay(s) may further include filter(s), enriching antigen(s), and buffer(s). Also described are methods of diagnosing and treating peritonitis in a subject who is a peritoneal dialysis patient that include utilizing the herein described assay(s) or assay kit(s) to analyze the subject's peritoneal dialysis effluent.
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 16/752,518, filed Jan. 24, 2020, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/799,430 filed on Jan. 31, 2019, the disclosure of each of which are incorporated herein by this reference.
- The application relates generally to medical devices, and more particularly to a diagnostic system, apparatus, and associated methods useful for, among other things, diagnosing and treating a peritoneal dialysis patient for peritonitis.
- Peritonitis is a major cause of morbidity and mortality in peritoneal dialysis (“PD”) patients globally. According to the International Society for Peritoneal Dialysis (“ISPD”) guidelines, peritonitis can be diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, e.g., abdominal pain and/or cloudy dialysis effluent (“CDE”); (2) dialysis effluent with a white blood cell count (“WBC”) greater than 100/μL or greater than 0.1×109/L (after a dwell time of at least two hours), with more than 50% of the WBCs being polymorphonuclear (“PMN”); and (3) a positive peritoneal dialysis effluent (“PDE”) culture.
- However, in practice, when a patient presents in the clinic with symptoms of peritonitis, it typically takes clinicians from a couple of hours to five days to get the results of a white blood cell count and peritoneal dialysis effluent cell culture. There is also about a 10% culture-negative rate even with infections. A fast, reliable way to confirm infection is needed to prevent patient deterioration due to delay in treatment.
- Once an infection diagnosis is made (without knowing the specific causative agent(s)), the nephrologist typically initiates empirical antibiotic therapy immediately. Such therapy typically includes administering at least two different broad spectrum antibiotics which collectively cover most of the gram-positive and gram-negative bacteria, along with an anti-fungal agent to prevent secondary fungal peritonitis until the causative agent(s) and drug susceptibility tests become available.
- The long-term use of broad spectrum antibiotics is however known to be associated with the risk of developing drug-resistant bacteria and an increased risk of subsequent fungal infection. Therefore, an early, rapid and culture-independent method is needed to identify the causative agent(s) of infection, support the prescription of suitable antibiotics, and reduce some of these unintended complications.
- At present, a simple device is not available for at-home peritoneal dialysis patients or for clinicians in dialysis clinics to confirm the presence of infection as well as to identify the putative causative agents or class of causative agents.
- A product from Mologic Ltd. (UK) detects certain inflammatory markers, such as IL-6 and MMP8, in peritoneal dialysis effluent to alert peritoneal dialysis patients of inflammation and encourage further investigation. However, the product does not specifically identify the causative agent(s) of infection, which would assist in, e.g., prescribing antibiotics. Furthermore, inflammation may be present in some cases where there is no infection, such as inflammation caused by chemical irritants, mechanical injury to the peritoneum, or other conditions. In such cases, inflammatory status alone does not provide sufficient information for a clinician to make a timely and specific decision about treatment.
- WO2018/060708 describes a method of chemically detecting leukocytes (e.g., using redox indicators), and optionally simultaneously discriminating between gram-positive and gram-negative bacteria in peritoneal dialysis effluent. However, the described method is not specific for causative agent(s) of infection, and requires incubation times of at least two hours, and more typically 12 hours or more. Another limitation of the method is that it may not distinguish between Gram negative infections and infection with both Gram positive and Gram negative bacteria.
- Other devices may be useful to determine gram status of bacteria in bodily fluids, but they cannot simultaneously detect inflammation, and/or they cannot indicate specific bacterial species known that may be associated with peritonitis.
- A turbidity check of peritoneal dialysis effluent is another technology used by the Renal Research Institute (“RRI”) and liberDi. Ronco C, Dell'Aquila R, Rodighiero M P (eds): “Peritoneal Dialysis: A Clinical Update,” Contrib. Nephrol., Basel, Karger, 2006, vol. 150, pp 187-194. The principle is to predict peritonitis by evaluating the WBC count based upon turbidity. However, there are many reasons other than just high levels of WBCs that can change the turbidity level in peritoneal dialysis effluent. Furthermore, the sensitivity of a turbidity-based WBC test may be inadequate for use with many continuous ambulatory peritoneal dialysis (“CAPD”) patients.
- Yet another technology from DxNow is a portable bio-imaging system with microfluidic-based consumables for prediction of peritonitis. The principle is to capture WBCs in peritoneal dialysis effluent using WBC-specific antibodies and then conducting a count. This technology is intended to provide an accurate WBC count in a short time, however, it does not provide any information regarding causative agents and the device is sophisticated and relatively expensive.
- Other platforms are based on PCR or other nucleic acid-based amplification/detection methodology. While these may be sensitive, they typically require bulky and expensive equipment, specialized training, and relatively long incubation periods (2+ hours), so may not be practical in many point-of-care applications where a determination is desired in minutes or less than an hour, particularly for use in the home or remote clinic setting
- Accordingly, despite a long-term need for rapid, early detection of inflammation and specific Gram/microbial status of peritonitis in PD patients, no suitable solution has yet been identified.
- The described system can be used to perform, from the perspective of the user, a single test with easy sample pre-treatment.
- Described is an assay for diagnosing an infection in a subject, which assay includes a first binding molecule that specifically binds an inflammatory marker in a sample taken from the subject, and a second binding molecule that binds a marker indicative of the presence of a pathogen in the sample. The first binding molecule and the second binding molecule may be present on one test device or test strip.
- Also described is an assay kit that includes a binding molecule that specifically binds an antigen indicative of an inflammatory response in the peritoneum; a binding molecule that specifically binds an antigen indicative of the presence of gram-positive bacteria; and a binding molecule that specifically binds an antigen indicative of the presence of gram-negative bacteria. Such an assay kit may further include a binding molecule that specifically binds an antigen indicative of the presence of a fungus. The assay kit may further include a secondary binding molecule or molecules capable of binding to the indicated binding molecules. The secondary binding molecules may be conjugated to a reporter or indicator, such as a fluorescent reporter or other colorable reporter, nanoparticle, reactive particle such as an enzyme, or other reporter or indicator. The binding molecules and secondary binding molecules may be, for example, antibodies.
- Typically, the antigen indicative of an inflammatory response in the peritoneum is neutrophil gelatinase-associated lipocalin (“NGAL”), interleukin 1 (“IL-1”), interleukin 6 (“IL-6”), interleukin 8 (“IL-8”), tumor necrosis factor a (“TNFα”), procalcitonin, and/or C-reactive protein (“CRP”). Lipoteichoic acid (“LTA”) is an antigen indicative of the presence of gram-positive bacteria. Lipopolysaccharide (“LPS”) is an antigen indicative of the presence of gram-negative bacteria. β-glucan is an antigen indicative of the presence of a fungus.
- For diagnosing peritonitis in a subject, the pathogen will typically be at least one bacterium and/or fungus.
- In certain embodiments, the assay/assay kit will include a binding molecule that specifically binds an antigen indicative of the presence of a specific pathogen species. For use with a peritoneal dialysis effluent, the specific pathogen will typically be Staphylococcus aureus, Pseudomonas sp., Staphylococcus epidermidis, Staphylococcus haemolyticus, Candida sp., Escherichia coli, vancomycin-resistant enterococci, and combinations thereof.
- Typically, the assay will be incorporated into a lateral flow device, which will produce results almost instantly, e.g., on the order of minutes. In general, a lateral flow device comprises one or more panels to detect one or more antigens.
- In one embodiment, multiple lateral flow devices can be integrated together to detect multiple antigens. Each lateral flow device comprising one or more panels may share a single sample reservoir.
- In another embodiment, multiple lateral flow devices can be kept in the same housing but separated to detect antigens by use of individual panels.
- In another embodiment, a single lateral flow device can be built in a multiplex format to detect multiple antigens using a single panel.
- The described assay(s)/assay kit(s) may further include means for filtering (e.g., a filter), concentrating (e.g., centrifugation), lysing cells, and/or enriching antigen(s) from the PDE.
- Sensitivity may be enhanced by concentrating the PDE, particularly for gram-positive and gram-negative antigens/markers. In certain embodiments, a syringe is used to filter and concentrate the PDE rather than a centrifuge.
- The described assay(s)/assay kit(s) may further include a buffer that specifically elutes antigen(s) from the assay kit. The buffer composition may be chosen to selectively stabilize the antigen and/or antigen-antibody complex, maintain pH, maintain or disrupt structure or binding of the antigen-antibody complex.
- Further described are methods of diagnosing peritonitis in a subject who is a peritoneal dialysis patient that include utilizing the herein described assay(s) or assay kit(s) to analyze the subject's peritoneal dialysis effluent.
- In certain embodiments, a method of diagnosing peritonitis in a subject who is a peritoneal dialysis patient includes detecting in a peritoneal dialysis effluent (“PDE”) from the subject an antigen indicative of an inflammatory response having been launched in the peritoneum; detecting (e.g., utilizing appropriate binding molecule(s)) in the PDE an antigen indicative of the presence of gram-positive bacteria; and detecting (e.g., utilizing appropriate binding molecule(s)) in the PDE an antigen indicative of the presence of gram-negative bacteria. Preferably, results are provided in less than an hour.
- In certain embodiments, the method further includes detecting (e.g., by utilizing appropriate binding molecule(s)) in the peritoneal dialysis effluent an antigen indicative of the presence of a fungus.
- In certain embodiments, the method further includes filtering, concentrating, and/or enriching the peritoneal dialysis effluent prior to detecting antigen(s). In certain embodiments, enrichment may be by, for example, placing 50 ml of PDE into a conical tube, followed by centrifugation of the PDE sample, and treatment with, e.g., a lysis buffer, extraction buffer, and neutralization buffer. Enrichment of a PDE sample for antigens may also be by use of an ultrafiltration (“UF”) membrane (e.g., molecular weight cutoff 29,000). In another embodiment, a syringe is used to pass/push the PDE through a UF membrane instead of a centrifuge.
- Such diagnostic methods can be used to treat peritonitis in the subject by first diagnosing the subject as having peritonitis and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the diagnosis.
- In a particularly preferred embodiment, a paper device that utilizes lateral flow assay technology and/or dry chemistry test technology is disclosed to simultaneously detect the presence of cell wall components and/or surface antigen(s) from contaminating microorganisms and/or inflammatory biomarkers in a patient's PDE. In some embodiments, lateral flow technology and/or dry chemistry test technology is used to rapidly assist clinicians in diagnosing an infection in the peritoneal dialysis patient when the patient presents in the clinic with cloudy peritoneal dialysis effluent and/or other symptoms of peritonitis. In certain embodiments, detection is based upon a lateral flow test (also known as a lateral flow immunochromatographic assay), which is a simple, paper-based device used to detect the presence of a target analyte in a liquid sample without the need for specialized and costly equipment. The device aids in the determination of the contaminating microorganism(s) so that, for example, appropriate antibiotics therapy can be promptly prescribed.
- The device and associated methods for using it assist clinicians (and patients and caregivers) in quickly determining the existence of an infection in a peritoneal dialysis patient and aid in providing treatment therefore so as to improve the management of peritoneal dialysis-related peritonitis. A goal is to thus rapidly and simultaneously detect the presence of multiple molecular markers that are released from the patient's host immune system and/or pathogens as soon as the invasion of pathogens is thought to have occurred in the patient.
-
FIGS. 1 through 5 and 7 depict various embodiments of lateral flow devices as described herein. -
FIG. 6 is a flow diagram of a process according to the disclosure. -
FIG. 8 is a flow diagram of a “test results driven approach.” -
FIG. 9 is a flow diagram of a “symptoms driven approach.” - As used herein, a “binding molecule,” e.g., an antibody (monoclonal or polyclonal) or antigen-binding fragment thereof, aptamer, affimer (peptide aptamer), receptor binding domain, or designed ankyrin repeat proteins (DARPins) is a molecule that specifically binds an antigen. The term “antigen-binding fragments” means a portion of an intact binding molecule, such as an antibody. Examples of antibody fragments include Fab, Fab′, F(ab′)2 and Fv fragments, CDR, antigen-binding site, heavy or light chain variable region, diabodies, triabodies single chain antibody molecules (“scFv”) and multi-specific antibodies formed from at least two intact antibodies or fragments thereof or peptides or polypeptides that contain at least a fragment of an immunoglobin that is sufficient to confer antigen binding to the peptide or polypeptide, etc. An antigen-binding fragment may comprise a peptide or polypeptide comprising an amino acid sequence of at least 2, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, or 250 contiguous amino acid residues of the amino acid sequence of the antibody. The antigen-binding fragments may be produced synthetically or by enzymatic or chemical cleavage of intact immunoglobulins or they may be genetically engineered by recombinant DNA techniques. The methods of production are well known in the art and are described, for example, in Antibodies: A Laboratory Manual, edited by: E. Harlow and D, Lane (1988), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. An antibody or antigen-binding fragment thereof has one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different. The term “specifically binding,” or “specifically recognize,” as used herein, in reference to the interaction of an antibody and its binding partner, e.g., an antigen, means that the interaction is dependent upon the presence of a particular amino acid sequence or structure, e.g., an antigenic determinant or epitope, on the binding partner. In other words, the antibody preferentially binds or recognizes the binding partner even when the binding partner is present in a mixture of other molecules or organisms. The binding may be mediated by covalent or noncovalent interactions or a combination of both. In yet other words, the term “specifically binding” or “specifically recognizes” means that the antibody is specifically immunoreactive with an antigenic determinant or epitope and is not immunoreactive with other antigenic determinants or epitopes. An antibody that specifically or immunospecifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., radioimmunoassays (“RIA”), enzyme-linked immunosorbent assays (“ELISA”), BIACORE, or other assays known in the art. Antibodies or fragments thereof that specifically bind to an antigen may be cross-reactive with related antigens, carrying the same epitope. Preferably, antibodies or fragments thereof that specifically bind to an antigen do not cross-react with other antigens.
- Analytes/associated specific binding molecules:
- In certain embodiments, the device is configured to detect one, two, or more inflammatory markers such as, e.g., neutrophil gelatinase-associated lipocalin (“NGAL”) and interleukin 6 (“IL-6”), as well as one, two, three, or more cell wall components, such as lipoteichoic acid (“LTA”), lipopolysaccharide (“LPS”), and β-glucan in one device.
- NGAL (neutrophil gelatinase-associated lipocalin, lipocalin 2, siderocalin, or neutrophil lipocalin) is a 25 kDa glycosylated single chain monomer and member of the lipocalin family of proteins that bind and transport small lipophilic molecules. NGAL is released by activated neutrophils, as well as renal tubule epithelial cells, cardiomyocytes, uterus, prostate, salivary glands, and other tissues, and can be found in both serum and urine. NGAL can form dimers, forming a 45 kDa disulfide-linked homodimer, small amounts of higher oligomers, and a 135 kDa heterodimer with matrix metalloproteinase 9 (“MMP-9,” gelatinase B). NGAL is involved in innate immunity. The homodimer form is specifically released by neutrophils that infiltrate into the peritoneum immediately after the invasion of a pathogen, while the monomer and heterodimer are more generally released by tubular cells and the other indicated tissues in response, for example, to acute kidney injury. During the process of peritonitis, the level of NGAL in peritoneal dialysis effluent correlates well with the quantity of neutrophils, and NGAL levels can be used to predict infection even before any clinical symptoms are noticed. With a lateral flow assay, detection of NGAL appears to be of a higher sensitivity than MMP8 in the peritoneal dialysis effluent samples.
- Antibodies that specifically bind NGAL are readily commercially available. For example, a goat IgG polyclonal antibody is available under Catalog #PAS-18382 from ThermoFisher Scientific. Anti-NGAL antibody (ab63929, rabbit polyclonal to NGAL), is available from Abcam (Cambridge, Mass., US).
-
Interleukin 6 is expressed and secreted by mesothelial cells, which serve as the first layer of the host defense system of the peritoneum. Once pathogens invade, the mesothelial cells upregulate expression of IL-6, and a higher level of IL-6 is thus detectable in the peritoneal dialysis effluent. IL-6 levels rapidly increase in the drained PDE before the onset of peritonitis, during peritonitis, and even after peritonitis. - Antibodies that specifically bind IL-6 are readily commercially available. For example, monoclonal antibodies MAB2061-SP, MAB2061-100, and MAB2061-500 (R&D Systems, Inc. Minneapolis, Minn., US) are human IL-6 antibodies that bind human IL-6 in direct ELISAs, but do not cross-react with recombinant IL-6 from mouse, rat, or pig. Anti-IL-6 antibody (ab6672, rabbit polyclonal to IL-6), is available from Abcam (Cambridge, Mass., US).
- IL-6 is however commonly detected in peritoneal dialysis patients (even without infection) due to the continuous irritation that may be caused by the peritoneal dialysis fluid. Therefore, the threshold of IL-6 detection limit is preferably adjusted in the device to more reliably indicate the existence of an infection. In this regard, IL-6 may not be the best marker to use, or may be better to use in combination with other inflammatory markers.
- In certain embodiments, IL-6 is replaced with a different inflammatory marker, such as procalcitonin or C-reactive protein (“CRP”). Both of these inflammatory markers are useful in the prediction of peritonitis.
- Other inflammatory markers include TNFα, fibrinogen, MPO, HAS, fMLP, A1AT, TIMP2, TIMP1, sICAM, MMP 9, HNE, cystatin C, IL-lb, IL-8, calprotectin, RBP4, MMP 8, MMP 2, desmosine, and SPD.
- Monoclonal antibodies against TNFα include infliximab (REMICADE™), adalimumab (HUMIRA™), certolizumab pegol (CIMZIA™), and golimumab (SIMPONI™).
- Antibodies that specifically bind fibrinogen are readily commercially available. For example, anti-fibrinogen antibody (ab189490, rabbit monoclonal to fibrinogen), is available from abcam (Cambridge, Mass., US). A polyclonal sheep anti-Human Fibrinogen antibody is available under Catalog #AF4786 from R&D Systems. This antibody detects human fibrinogen in direct ELISAs and Western blots.
- Antibodies that specifically bind procalcitonin are readily commercially available. For example, anti-procalcitonin antibody (ab166963, sheep polyclonal to procalcitonin), is available from Abcam (Cambridge, Mass., US). A mouse procalcitonin monoclonal antibody (27A3) is available under Catalog #MA1-20887 from ThermoFisher Scientific. MA1-20887 detects procalcitonin in human samples and has been successfully used in ELISA and Western blot procedures. The MA1-20887 immunogen is an internal fragment of purified, full length, native human calcitonin.
- Antibodies that specifically bind to C-reactive protein (“CRP”) are readily commercially available. For example, anti-C Reactive Protein antibody (ab31156, rabbit polyclonal to human CRP), is available from Abcam (Cambridge, Mass., US). A mouse CRP monoclonal antibody (P4D7) is available under Catalog #MIC0501 from Invitrogen Antibodies/ThermoFisher Scientific.
- Thus, increased levels of NGAL and IL-6 in the peritoneal dialysis effluent indicate both the activation of innate immunity and that there is a host defense in the peritoneum, which are initiated at the beginning of peritonitis.
- In certain described embodiments, the device could also use only a gram-positive inflammatory marker(s) with an additional technology. For example, in certain embodiments, using turbidity detection technology (e.g., that of RRI) in combination with a binding molecule that binds a marker indicative of the presence of a pathogen could obviate the use of a binding molecule for an inflammatory marker.
- Thus, in certain embodiments, described is a method of treating peritonitis in a subject who is a peritoneal dialysis patient, the method comprising: first determining if turbidity is present in a peritoneal dialysis effluent, analyzing the subject's peritoneal dialysis effluent to determine the identity of an infectious microorganism (e.g., Gram (+), Gram (−) and/or fungal infection), and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the determination of the identity of the microorganism.
- In certain embodiments, turbidity detection may be used in combination with a binding molecule that binds a marker indicative of the presence of a pathogen and a binding molecule that binds an inflammatory marker. Such a combination of indicators can provide additional benefits to the patient or clinician, particularly in early diagnosis of infection and early characterization of specific agents of infection.
- Peptidoglycan is a key component of the cell wall of bacteria and thus serves as a reliable marker of bacterial infection, distinguishing other causes of inflammation and/or infection.
- Lipoteichoic acid (“LTA”) is a glycerol phosphate surface polymer component of the envelope of Gram− positive bacteria. LTA is anchored via its glycolipids to the membrane and carries a polysaccharide chain extending into the peptidoglycan layer of the cell wall. LTA is released spontaneously into the culture medium during growth of gram-positive bacteria. LTA functions as an immune activator with characteristics very similar to lipopolysaccharide (LPS) from Gram− negative bacteria. LTA binds to CD14 and triggers activation predominantly via Toll-like receptor 2. Although LTA is internalized and traffics to the Golgi, cellular activation in response to LTA occurs at the cell surface.
- Antibodies that specifically bind to LTA are readily commercially available. For example, a mouse monoclonal antibody is available under Catalog #MA1-40134 from ThermoFisher Scientific. MA1-40134 detects LTA from gram-positive bacterial samples, and has been successfully used in Western blot, ELISA, flow cytometry, immunofluorescence, and immunohistochemistry (frozen) applications. Another mouse monoclonal antibody (IgG3) is available under Catalog #GWB-9E3242 from Genway Biotech, Inc. (San Diego, Calif., US). Other mouse monoclonal LTA antibodies are available, for example, under Catalog #LS-C102921, LS-C102920, LS-C202488, and LS-C757317 from LifeSpan Biosciences, Inc. (Seattle, Wash., US).
- LPS is a cell wall component of gram-negative bacteria. Antibodies that specifically bind LPS are readily commercially available. For example, a rabbit polyclonal antibody preparation is available under Product No. PAB526Ge01 from Cloud-Clone Corp. that has the ability to recognize LPS in immunohistochemical staining and western blotting. A lipopolysaccharide (LPS) mouse monoclonal antibody is available under Catalog No. CAU29364 from Biomatik (Cambridge, Ontario, CA).
- β-glucan is a cell wall component of fungi. Antibodies that specifically bind β-glucan are readily commercially available. See, also, U.S. Pat. No. 7,893,219 to Cassone et al. (Feb. 22, 2011), the contents of which are incorporated herein by this reference.
- LTA, LPS, and β-glucan are cell wall components of gram-positive bacteria, gram-negative bacteria, and fungi, respectively. The presence of such cell wall component(s) in the patient's peritoneal dialysis effluent is indicative both that infection is occurring and the specific type of causative agent(s).
- In certain embodiments, other specific antigens can be detected to indicate the presence of the specific pathogen (e.g., bacteria) species in the peritoneal dialysis effluent. Commonly, such specific pathogens are selected from the group consisting of Staphylococcus aureus, Pseudomonas spec., Staphylococcus epidermidis, Staphylococcus haemolyticus, vancomycin-resistant enterococci, Candida sp., Escherichia coli, and mixtures thereof.
- For example, lysostaphin could be used to detect Staphylococcus aureus and exotoxin A could be used to detect Pseudomonas spec. Monoclonal and polyclonal anti-lysostaphin antibodies are commercially available from Antibody Research Corporation (St. Peters, Mo., US) under the SKUs 111145 and 111135, respectively. Polyclonal anti-Pseudomonas Exotoxin A antibodies produced in rabbit are available from Sigma-Aldrich/Millipore SiGMa under the MDL number MFCD00162779. Similarly, Staph. aureus-specific peptidoglycan can be used to specifically detect Staph. aureus in PDE. Monoclonal antibodies are available from QED Biosciences, Inc. (San Diego, Calif., US) under the Catalog Nos. 15702, 15703, and 15704; from Meridian Life Science, Inc. (Memphis, Tenn. US) under the Catalog No. C55570M, and from Abcam, Inc. (Cambridge, Mass., US) under the Product name ab37644. These antibodies recognize peptidoglycan of Staph. aureus, Protein A-negative Staph. aureus, and Staph. epidermidis.
- Treatment Regimens:
- Single agent antibiotics for treating peritonitis include ertapenem (INVANZ™), cefoxitin, doripenem (DORIBAX™), imipenem/cilastatin (PRIMAXIN™), ertapenem, imipenem/cilastatin, meropenem (MERREM™), moxifloxacin (AVELOX™), piperacillin/tazobactam (ZOSYN™), ticarcillin/clavulanate, piperacillin/tazobactam, ticarcillin/clavulanate (TIMENTIN™), and tigecycline (TYGACIL™).
- Combination therapy antibiotics include cefepime (MAXIPIME™), cefotaxime (CLAFORAN™), ceftazidime (FORTAZ™), or ceftriaxone (ROCEPHIN™), together with metronidazole (FLAGYL™). Or cefazolin, cefotaxime, ceftriaxone, ciprofloxacin (CIPRO™), levofloxacin (LEVAQUIN™), together with metronidazole. Or cefepime, ceftazidime, ciprofloxacin, levofloxacin, together with metronidazole. Or gentamicin or tobramycin together with clindamycin (CLEOCIN™) or metronidazole (with or without ampicillin). Such antibiotics are typically administered per established protocols.
- In treating peritonitis, regimens of imipenem, piperacillin/tazobactam, and a combination of aminoglycosides and metronidazole are often effective.
- Antibiotic treatment against Pseudomonas sp. typically involves administration of one or more of the following antibiotics: ceftazidime, ciprofloxacin or levofloxacin, gentamicin, cefepime, aztreonam, carbapenems, ticarcillin, and/or ureido penicillins.
- Penicillinase-resistant penicillins (flucloxacillin, dicloxacillin) are antibiotics for treating serious methicillin-susceptible S. aureus (“MSSA”) infections, but first generation cephalosporins (cefazolin, cephalothin and cephalexin), clindamycin, lincomycin and erythromycin are used in less serious MSSA infections or in patients with penicillin hypersensitivity. All serious MRSA infections should be treated with parenteral vancomycin or teicoplanin. Nosocomial strains of MRSA are typically multi-resistant (“mrMRSA”); mrMRSA strains may be treated with a combination of two oral antimicrobials, such as rifampicin and fusidic acid. Lincosamides (clindamycin, lincomycin) or cotrimoxazole may be used to treat less serious MRSA infections. Antibiotics such as linezolid and quinupristin/dalfopristin have anti-staphylococcal activity.
- Lateral Flow Devices:
- A lateral flow assay (“LFA”) (also known as a lateral flow test (“LFT”), lateral flow device (“LFD”), lateral flow immunoassay (“LFIA”), lateral flow immunochromatographic assays, “Dipstick,” Pen-side test, Quick/Rapid test, or test strip) is a simple to use diagnostic device to confirm the presence or absence of target analytes, such as pathogens or biomarkers in humans or animals.
- Lateral flow assays typically have a control line to confirm that the test is working properly, along with one or more target or test lines. They are designed to incorporate intuitive user protocols and require minimal training to operate. They can be qualitative and read visually, or quantitative when combined with reader technology, such as ADxLR5®.
- Lateral flow tests are widely used in human health for point-of-care testing. They can be performed by a healthcare professional or by the patient, and in a range of settings including the laboratory, clinic, or home.
- Lateral flow assays can be developed to be used in a dipstick format or in a housed cassette. Both dipsticks and housed tests will work in a similar way, dependent on the industry, sample matrix, and the market requirement.
- Although a “competitive assay” could be adapted for use herein (e.g., by utilization of an enrichment method such as centrifugation to increase the sensitivity of detection), sandwich (or “non-competitive”) assays are typically preferred for use herein. In a non-competitive immunoassay format, a positive test is typically represented by the presence of a colored line at the test line position. A non-competitive immunoassay format is ideal for large molecular weight analytes with multiple antigenic sites. Generally, non-competitive immunoassays have a lower limit of detection (heightened analytical sensitivity) compared to a competitive format. Typically, non-competitive immunoassays can detect on the order of picograms/mL (parts per trillion) in comparison to nanograms/mL (parts per billion) for the competitive assay format.
- Lateral flow devices typically utilize immunoassay technology with a nitrocellulose membrane, colored latex nanoparticles (or labels such as magnetic beads or colored styrene balls), and antibodies, for quick analysis (see, e.g.,
FIG. 1 ). - When a sample from a peritoneal dialysis effluent is added to the lateral flow device, the sample flows along the test device passing through a conjugate pad into a nitrocellulose membrane and then onto an absorbent pad to absorb excess sample.
- The sample pad acts as the first stage of the absorption process, and in some cases contains a filter to ensure the accurate and controlled flow of the sample. The conjugate pad, which stores the conjugated labels and antibodies, receives the sample. If the target is present, the immobilized conjugated antibodies and labels bind to the target and continue to migrate along the test.
- As the sample moves along the device, the binding reagents situated on the nitrocellulose membrane bind to the target at the test line. A colored line forms and the density of the line varies depending on the quantity of the target present. Some targets may require quantification to determine the target concentration such as by using a reader.
- Multiplexed lateral flow assays, related methods, and devices are disclosed in U.S. 20050250141A1 to Lambert et al., (Nov. 10, 2005), the contents of which are incorporated herein by this reference, which assays are capable of simultaneously detecting multiple analytes. See also U.S. Pat. No. 6,924,153 B1 to Boehringer et al. (Aug. 2, 2005), U.S. Pat. No. 8,128,871 B2 to Petruno et al. (Mar. 6, 2012), and U.S. Pat. No. 7,785,899 B2 to Saul et al. (Feb. 18, 2005), the contents of each of which are incorporated herein by this reference, for various lateral flow test kits capable of detecting multiple analytes.
- Conjugate labels used with lateral flow devices include: colloidal gold, cellulose nanobeads, fluorescent latex, paramagnetic particles, up-converting phosphors, and various fluorescent labels.
- In certain embodiments, the cell wall components are detected by dry chemistry if, for example, the specificity of the antibodies in the lateral flow test is inadequate. Dry chemistry is based upon specific recognition of cell wall component(s) by, e.g., enzymes.
- Alternatively, a more sophisticated system can be used to acquire quantitative data instead of qualitative data. For example, the immunofluorescence technology together with a reader may be utilized to measure the quantity of markers in peritoneal dialysis effluent to provide more information to the patients and clinicians by comparing the obtained values with a predetermined cutoff value.
- The detection of each biomarker or cell wall component is preferably carried out in an individual channel, although all detections are made simultaneously by using the same peritoneal dialysis effluent sample. Such a design can prevent cross-reaction between biomarkers or cell wall component(s).
- It is preferred to add peritoneal dialysis effluent sample to each channel. But alternatively, more than one channel can be connected to each other to avoid repeatedly adding the peritoneal dialysis effluent sample. Accordingly, described is a point-of-care device and assay for testing for peritonitis in dialysis effluent, especially in peritoneal dialysis effluent, providing several advantages over conventional assays and improving peritonitis management. The device and methods are inexpensive, rapid, and easy to use by a patient or clinician with only limited training. Also described is a device and method for such testing that will rapidly allow identification of specific microbial agents of peritonitis or other infection, decreasing the time needed to confirm a peritonitis diagnosis, to facilitate early determinations of an optimal treatment regimen (e.g., specific antibiotic therapy or mixed therapy), with the possibility to replace culture testing and hospital-based laboratories altogether, where both sensitivity and specificity of testing are equivalent to laboratory methods.
- A particular advantage is that the disclosed device and assay combines both inflammatory marker testing and specific infection agent testing in a single, inexpensive, and simple to use device. The device and assay gives the patient and clinician substantially more information about actual infection and appropriate peritonitis management than previous technology. For example, tests looking only at inflammatory status rely exclusively on non-specific markers of infection. Even if the test is positive for one or more inflammatory markers (alone), the clinician does not gain significant information about which specific type of therapy (e.g., specific type of antibiotic) to prescribe. The disclosed assay adds an agent-specific test (e.g., Gram status, specific bacterium, fungus, etc.) to the inflammatory marker, greatly increasing reliability of the diagnosis of pathogen-associated peritonitis, while reducing the time needed to implement the most appropriate therapy. Further, PDE samples according to the disclosed assay and device do not necessarily require pre-treatment or any special processing before they are applied to the device, so patients can perform the entire test in their homes immediately. As a result, rather than prescribing, for example, an empiric, broad-spectrum antibiotic in response to a generalized confirmation of peritonitis, the clinician can quickly prescribe a targeted antibiotic that is most suitable for treating a known Gram positive or Gram negative bacterial infection. The combined device is also cheaper and easier to use and interpret than two devices or multiple assays, and results can be read in less than 10 minutes in most cases.
- In this way, patients can be treated sooner with a much higher probability of being administered with, for example, the most suitable antibiotic for their infection. In some settings, a patient in a home setting could accordingly test their own PDE, identify a specific positive result and report to their clinician, and be directed to begin a course of targeted treatment immediately. Such therapy could be initiated even where other classical signs of infection (e.g., pain, fever, cloudy effluent) are not yet present. Further, the severity and duration of peritonitis in, for example, PD patients may be reduced, allowing them to stay on PD longer without the need for more invasive forms of dialysis, such as hemodialysis. Also reduced is the use of improper antibiotics (i.e., empiric, broad-spectrum antibiotics where a more targeted therapy is indicated), thus reducing the incidence of antibiotic-resistant bacteria in the population.
- In certain embodiments, a picture is taken of the results of the test, which are transmitted to a health care practitioner. In certain embodiments, a mobile telephone “app” is used to analyze the results, and provide the patient with a notation to, for example, “Call your health care provider” or “Peritonitis Confirmed.” In certain embodiments, this can further include analysis of a picture of the analyte, using technology as described in International Application No.: PCT/EP2017/000803 (International Publication No. WO 2018/007013 published on Jan. 11, 2018), the contents of which are incorporated herein by this reference.
-
FIGS. 1 through 5 and 7 illustrate various embodiments of a lateral flow device according to the invention. In the depicted cases, the device is configured to detect NGAL, LTA, β-glucan, LPS, and IL-6 in one test. - As depicted in
FIG. 1 , a volume of analyte (e.g., PDE) is deposited into a well portion of the strip. The PDE flows away from the well (e.g., by capillary action), down the strip, and interacts with a conjugate of appropriate labeled antibodies associated with the strip. Other antibodies having the same specificity as the labeled antibodies are affixed to the strip (at the solid phase). If the appropriate antigen is present in the PDE (e.g., NGAL, LTA, β-glucan, LPS, or IL-6), it will bind with the labeled antibodies and form a sandwich complex at the portion of the strip where the solid phase antibodies are present, and the sandwich complex will be detectable. A control line is further depicted to ensure the POCT is performing properly. Excess reagent passes to the end of the strip. -
FIGS. 2 and 3 represent various configurations of a lateral flow device according to the disclosure (andFIG. 1 ), including four sample wells and four roughly-parallel and adjacent channels configured to detect LTA, LPS, NGAL, and IL-6. This embodiment has the advantage of taking up relatively little space, while requiring application of four relatively low-volume PDE samples to utilize all four channels. InFIGS. 2 and 3 , the control lines are distal from the wells and test lines closer to the wells. -
FIGS. 4 and 5 represent an alternative configuration of a lateral flow device of the disclosure, including a single, central sample well and four channels that radiate away from the central well, configured again to detect LTA, LPS, NGAL, and IL-6. This embodiment has the advantage of requiring only one sample of PDE to be applied by the patient or clinician. -
FIGS. 2 and 4 also indicate possible dimensions (in millimeters) for the lateral flow device and ranges for such dimensions, according to certain embodiments. For example, the device depicted inFIG. 2 can have awidth 38 with a Range of 30˜60 mm and a Tolerance of −1˜+1, aheight 70 having a Range of 55˜100 mm and a Tolerance of −1˜+1, depicteddistance 60 having a Range of 50˜80 mm and a Tolerance of −1˜+1, and depicted width 4 of the channel having a Range of 2.5˜8 mm and a Tolerance of −1˜+1. The device depicted inFIG. 4 can have, e.g., a height andwidth 90 with a Range of 70˜120 mm and a Tolerance of −1˜+1, depicteddistance 60 having a Range of 50˜80 mm and a Tolerance of −1˜+1, and depicted width of the channel having a Range of 2.5˜8 mm and a Tolerance of −1˜+1. -
FIG. 7 illustrates a triple-chevron configuration (e.g., FRESENIUS™ logo), to which sample is applied to the center of each chevron. The sample then flows laterally or longitudinally along multiple channels to test lines where appropriate and binding reagents bind antigens that may be present in the samples. - It is preferred to read the results of all analytes at the same time point, for instance, after 15-30 minutes. Alternatively, the results can be read consecutively.
- The described samples are peritoneal dialysis effluents. In an embodiment, the peritoneal dialysis effluent is used directly after draining to detect one or more markers of infection. In a preferred embodiment, the peritoneal dialysis effluent is first concentrated and/or filtered, and subsequently used to detect one or more markers of infection.
- The shape of the device has no limit so long as the individual channels are maintained.
- Although a lateral flow immunoassay is preferred, other techniques such as quantitative immunofluorescence, dry chemistry, etc. can be adapted for use herein.
- Methods: In certain embodiments, after a patient has presented in the clinic with a cloudy peritoneal dialysis effluent and/or other symptoms of infection, the practitioner can quickly use the device before sending samples for WBC count and culture. The practitioner can then interpret the results and provide to the nephrologist or supervisor the test results, symptoms, history, etc., along with a possible antibiotics prescription(s).
- Alternatively, the device can be used at home by patients. The patient should inform the clinician(s) of the results immediately and follow the suggested instructions for treatment, e.g., orally taken antibiotics, or adding antibiotics directly into fresh dialysis solution for the next exchange. This may happen, for example, outside of clinic hours or for those patients who live in a rural area, without having to wait to present at clinic before implementing a necessary therapeutic regimen.
- Alternatively, the device can be used by clinician(s) or the patient to determine whether the prescribed treatment has been effective.
- In embodiments, the device is utilized as part of an integrated care management protocol. In certain embodiments, results determined by the device are processed by one or more portable electronic devices (e.g., smartphone app, computer, tablet, etc.) and may be associated with a digital application. The results may in turn be integrated via a cloud or network-based communication path to a remote clinician, laboratory, or other health professional for further evaluation and instruction. Such a remote professional may then direct appropriate clinical action by the patient or on-site professional, such as directing immediate administration of an appropriate antibiotic or other therapy, direct the patient to come to the clinic, or otherwise indicate appropriate care. In some embodiments, a remote professional can send an electronic code to open a medicine lockbox, for example, in the patient's home, with the appropriate medication.
- In other embodiments, one or more clinical protocols (i.e., “decision trees”) utilizing the described device and/or method are disclosed. Such protocols may be a “test results driven approach” (
FIG. 8 ) as, for example, initiated in response to an observable indicator of infection such as turbidity, or may be “symptom driven” (FIG. 9 ) as for example may be initiated by a patient symptom such as pain or fever. - The “Test results driven approach” of
FIG. 8 is applicable to scenarios when turbidity is captured automatically on each treatment, or when the patient undergoes a turbidity test manually after his or her dialysis treatment. As depicted inFIG. 8 , if Turbidity is positive (“Turbidity+” 20), then a Point of Care Test (“POCT”) as described herein is administered. - If the POCT is positive (“POCT+” 22), then the results of the POCT are analyzed in an attempt to determine the etiology of the infection and appropriate follow up administered. For example, if the etiology of the infection is inconclusive 24, then the patient is requested to seek
clinical evaluation 26. If the etiology of the infection is determined to be a Gram+ bacteria (“Gram+”), then an appropriate antibiotic 28 (or other acceptable treatment) is prescribed for the patient. If the etiology of the infection is determined to be a Gram negative bacteria (“Gram−”), then an appropriate antibiotic 30 (or other acceptable treatment) is prescribed for the patient. - If the POCT is negative (“POCT−” 32), then “no further action” 34 may be needed with respect to the patient. However, with respect to this “No further action*” field under the “POCT−” field of the diagram, this assumes, for example, that the point of care test strip's specificity is sufficient to exclude peritonitis (e.g., both bacterial and fungal causes). Thus, in the situation where Turbidity is positive 20, but the POCT is negative 32, the decision tree says “No further action,” but it could alternatively be “Seek clinical evaluation” depending on the particular POCT used. For example, if the POCT only identifies bacterial peritonitis, but not other causes of peritonitis (e.g., fungal peritonitis), a patient should still proceed with a clinical evaluation to define the etiology of the turbidity (not shown). A similar situation occurs with the situation Turbidity negative (or inconclusive) 36 with Symptoms positive 38, even if the POCT is negative 40, where the decision tree states “No further action*” 42, a different etiology other than bacterial peritonitis should be considered and a clinical evaluation could be necessary.
- In
FIG. 8 , when Turbidity is negative or inconclusive 36, Symptoms are positive 38, and a POCT is positive 44, the treatment is as before. For example, if the etiology of the infection is inconclusive 46, then the patient is requested to seekclinical evaluation 48. If the etiology of the infection is determined to be a Gram+bacteria (“Gram+”), then an appropriate antibiotic 50 (or other acceptable treatment) is prescribed for the patient. If the etiology of the infection is determined to be a Gram negative bacteria (“Gram−”), then an appropriate antibiotic 52 (or other acceptable treatment) is prescribed for the patient. - In
FIG. 8 , if Turbidity is negative or inconclusive 36 and Symptoms are negative 54, then generally, no further action is required 56. - The “symptoms driven approach” of
FIG. 9 can be used, for instance, when turbidity is not captured automatically, or when the patient does not undergo a turbidity test after his or her treatment. Under such circumstances, when Symptoms are negative 58, no further action is required 60. However, when Symptoms are positive 62 and a Turbidity test results negative 64, furtherclinical evaluation 66 is indicated. - When in
FIG. 9 , Symptoms are positive 62 and a Turbidity test is either positive or not conducted 68, a POCT is preferably conducted. - In
FIG. 9 , if the POCT is negative 70, nofurther action 72 may be necessary. Again however, with respect to the “No further action*”field 72 under field “POCT−” 70 of the decision tree, this assumes that the POCT strip(s)'s specificity is sufficient to exclude all etiologies for peritonitis. As with the test results driven approach ofFIG. 8 , in the “Symptoms driven approach” decision tree ofFIG. 9 , in the situation Symptoms positive 62 with Turbidity positive (or unavailable) and the POCT negative 72, the recommendation rather than “No further action” would be to “Seek clinical evaluation” (not shown) to rule out, for instance, a fungal etiology. - In
FIG. 9 , when Turbidity is positive or unavailable 68 and a POCT is positive 74, the treatment is as the Test results driven approach. For example, if the etiology of the infection is inconclusive 76, then the patient is requested to seekclinical evaluation 78. If the etiology of the infection is determined to be a Gram+bacteria (“Gram+”), then an appropriate antibiotic 80 (or other acceptable treatment) is prescribed for the patient. If the etiology of the infection is determined to be a Gram negative bacteria (“Gram−”), then an appropriate antibiotic 82 (or other acceptable treatment) is prescribed for the patient. - Also, in the Symptoms driven approach, with Symptoms positive and Turbidity negative, one could still beneficially utilize the POCT to benefit the patient (not shown). If the POCT results positive, the same follow up treatments can be used. If the POCT is negative, use “Seek clinical evaluation.”
- In alternative embodiments of the decision trees, turbidity may be eliminated entirely as a required test, and the decision to implement POCT testing may be driven entirely by the presence or absence of symptoms. This may be the case where, for example, turbidity data is inconclusive or unreliable, or where the clinician or patient wants to expedite the POCT testing, as may be the case where the patient has a history of a specific type or types of peritonitis infections and the primary interest is in narrowing the most likely cause of infection quickly.
- In the various approaches, if the POCT is configured to detect the presence of, e.g., a fungal infection (not shown), and this tests positive, then an appropriate antifungal agent and/or therapy may be prescribed.
- An advantage of such protocols is that they can be performed remotely, as by a patient in the home or at a remote clinic, and they can exploit the point of care testing device to rapidly identify a causative agent of infection and rapidly institute suitable treatment (e.g., specific antibiotics). In other cases, these protocols can be performed in a clinic with little additional training required of the practitioner, but nevertheless reducing time to appropriate treatment over conventional protocols.
- The invention is further described with the aid of the following illustrative Examples.
- The assay of
FIGS. 1-3 is made with the following antibody components incorporated into a paper-based (e.g., nitrocellulose) LFD: -
Binding Molecule(s) Supplier Product No. Reference Anti-IL-6 R&D Systems MAB206 (Capture) Cell. Physiol. 614 McKinley Place NE Biochem., 2017; Minneapolis, MN 55413 42(5):1961-1972 R&D Systems BAF206 (Detection) Cell. Physiol. 614 McKinley Place NE Biochem., 2017; Minneapolis, MN 55413 42(5):1961-1972 Abcam ab48478 (Pair) 1 Kendall Square, Suite B2304 Cambridge, MA 02139-1517 Anti-NGAL R&D Systems MAB17571 (Capture) 614 McKinley Place NE Minneapolis, MN 55413 R&D Systems BAF1757 (Detection) J. Neurosci. 2016; 614 McKinley Place NE 36(20):5608-22 Minneapolis, MN 55413 Abcam ab220126 (Pair) 1 Kendall Square, Suite B2304 Cambridge, MA 02139-1517 Anti-LPS Meridian Bioscience C55308M 3471 River Hills Drive Cincinnati, OH 45244 Anti-LTA Meridian Bioscience C65380M * 3471 River Hills Drive Cincinnati, OH 45244 Meridian Bioscience C65813M * 3471 River Hills Drive Cincinnati, OH 45244 Anti-Staph. Abcam ab37644 aureus 1 Kendall Square, Suite B2304 (peptidoglycan) Cambridge, MA 02139-1517 QED Bioscience, Inc. 15704 10919 Technology Pl # C, San Diego, CA 92127 Meridian Life Science, Inc. C55570M (Detection) 5171 Wilfong Road Memphis, TN 38134 Invitrogen, Inc. MA1-10708, and Waltham, MA MA1-10709 (Pair) - Antibody list: capture antibody, detector antibody (BSA gold conjugated), anti-biotin gold antibody.
- Three drops of PDE sample are placed onto the sample receiving portions of each of the wells of the device shown in
FIG. 1 , fluid flows into each of the channels and moves by diffusion through the nitrocellulose paper to a capture zone containing a capture (i.e., primary) antibody, and from there continues to a detection zone within a detection window containing one or more detection (i.e., secondary) antibodies. Results are read visually or using an optical reader, mobile device, or similar to determine if the PDE sample is positive for one or more markers of infection and/or inflammation. - Protocol—Rapid PD-related peritonitis diagnosis at dialysis clinic or home (following the flow diagram of
FIG. 6 ). - Background: When a PD patient displays any sign of peritonitis (e.g., cloudy PDE, abdominal pain, and/or fever), he or she is to visit a dialysis clinic or doctor as soon as possible. Upon presentation at the dialysis clinic, the nurse or other health care professional drains the PD effluent into a waste bag and collects samples for routine testing such as cell count, gram stain, and culture. Alternatively, a PD patient may collect and test samples using the disclosed assay and device before going to a dialysis clinic or doctor. What follows is rapid testing of the same PDE sample before it is sent for routine testing (e.g., cell culture, Gram stain, cell count, etc.)
- 1. Process
-
- 1.1 Equipment and reagents
- 1. PPE (“Personal Protective Equipment”)
- 2. Testing kit contains:
- A sterile 50 mL syringe with a needle pre-attached
- A sterile 10 mL syringe with a needle pre-attached
- Two transparent calibrated droppers
- A sterile 50 mL conical tube with a filter pre-assembled on the top
- A sterile 50 mL conical tube
- A vial with 10 mL elution buffer
- A testing device
- 1.2 Procedure
- 1. Perform hand hygiene and wear PPE.
- 2. Clean work surface with detergent.
- 3. Unwrap the testing kit and gather the materials for use.
- 4. Follow the clinic's standard operating procedures to drain the PDE into the drain bag and label the bag.
- 5. Use a sterile syringe to take 45 mL PDE sample through the injection port on the drain bag.
- 6. Discard the needle.
- 7. Attach the syringe to a round filter (Ø50 mm) which is pre-assembled with a 50 mL conical tube.
- 8. Push the 45 mL PDE sample into the conical tube through the filter.
- 9. Take out the testing device and place it on the flat and clean work surface.
- 10. Disassemble the filter and assemble it to the other sterile 50 mL conical tube.
- 11.
Transfer 5 mL of PDE sample that is collected in step 8 and dispense 5 drops (˜0.25 mL) into the 1st sample reservoir on the testing device of EXAMPLE I. - 12. Wait for 15 minutes to read the results by checking the color of the two lines.
- 13. During the waiting time, use the other syringe to collect all the elution buffer in the vial.
- 14. Discard the needle.
- 15. Attach the syringe to the filter that was assembled to the other conical tube at
step 10. - 16. Push the elution buffer into the conical tube through the filter.
- 17.
Transfer 5 mL of PDE sample that is collected in step 16 and dispense 5 drops (˜0.25 mL) into the 2nd sample reservoir on the testing device. - 18. Wait for another 10-15 minutes to read the results.
Send the drain bag to lab for other testing.
- 1.1 Equipment and reagents
- Enrichment by UF Membrane
- 25 ml of PDE is placed into a container for centrifugation, which is separated into an upper chamber and a lower chamber by an ultrafiltration (“UF”) membrane having a molecular weight cutoff of 29,000. The container is capped and placed into a centrifuge and spun (×4000 g). The PDE is filtered through the UF membrane and pushed from the upper chamber to the lower chamber, creating an enriched PDE.
- A few drops of the enriched PDE are placed onto the sample port of the IL-6/NGAL panel of the device of EXAMPLE I, and any reaction is determined.
- The UF membrane is mixed with elution buffer, and a few drops are placed onto the sample port of the LPS/LTA panel of the device of EXAMPLE I, and any reaction determined.
- Detection of Inflammatory and Gram status markers in PDE samples
- 87 PDE samples were recruited, including 9 Peritonitis samples and 78 Non-peritonitis samples. NGAL and IL-6 reference levels for each sample were determined with JiuQiang biochemistry NGAL test and the SIEMENS chemiluminescence IL-6 test.
- A device corresponding to
FIGS. 2 and 3 was used to analyze the samples. The assay had 4 strips corresponding to NGAL, IL-6, LTA, and LPS. NGAL and IL-6 were used as inflammatory indicators for peritonitis. LTA was used as an indicator of Gram positive bacterial infection. LPS was used as an indicator for Gram negative bacterial infection, with the following reagents associated with each of the relevant strips: - NGAL:
- a) Control line: ShangDong ShuoJing Goat-anti-mouse antibody
- b) Test line: NanJing GenScript NGAL Antibody (4C10A7)
- c) Conjugate: NanJing GenScript NGAL Antibody (5A9D12)
- d) Nitrocellulose membrane: Millipore HF13502S18
- e) The limit of detection of the NGAL test was optimized at 80 ng/ml.
- IL-6
- a) Control line: ShangDong ShuoJing Goat-anti-mouse antibody
- b) Test line: Novoprotein (DA012)
- c) Conjugate: Novoprotein (DA011)
- d) Nitrocellulose membrane: Millipore HF13502S18
- e) The limit of detection of IL-6 test was optimized to be 200 pg/ml & 300 pg/ml
- LTA
- a) Control line: ShangDong ShuoJing Goat-anti-mouse antibody
- b) Test line: Streptavidin Hangzhou KuaiGe technology (20190307-1)
- c) Conjugate: Biorbyt (orb23891)
- d) Biotinylation: Biorbyt (orb23822)
- e) Nitrocellulose membrane: Millipore HF13502S18
- LPS
- a) Control line: HangZhou LongJi biotech (lot 181114)
- b) Test line: Thermo Fisher PA1-73178
- c) Conjugate: Thermo Fisher PA1-28903
- d) Nitrocellulose membrane: Millipore HF13502S18
- Test results were visually read, with a negative result indicated if the control line was positive and test line was negative; and a positive result indicated if the control line and test line were positive. See
FIGS. 1-3 . - All 87 PDE samples were tested with the device of
FIG. 1 for the NGAL test and IL-6 test. 78 non-peritonitis samples were tested for LTA and LPS. The following Tables show the results. -
TABLE A Specificity for NGAL, IL-6, LTA, and LPS in Peritoneal Dialysis Effluents IL-6 NGAL6 + NGAL 200 IL-6 200 LTA LPS Testing number 78 78 78 78 18 Negative result 56 66 70 75 18 Specificity 56/78 66/78 70/78 75/78 18/18 71.8% 84.6% 89.7% 96.6% 100% -
TABLE B Sensitivity for NGAL and IL-6 in PDE NGAL/IL-6 NGAL IL-6 200 200 Testing number 9 9 9 Positive result 9 9 9 Sensitivity 9/9 9/9 9/9 100.0% 100.0% 100.0% - As can be seen, the combination of the
NGAL 80 ng/ml & IL-6 200 pg/ml combination indicator presents the best sensitivity and specificity for these markers in peritonitis detection. In the same experiments, the specificity for LTA was 96.6% and for LPS was 100%. - The sensitivity for LTA and LPS in the described PDE samples was separately tested using spiked bacterial peritoneal dialysis samples and negative peritoneal dialysis samples for comparison. Three Gram positive bacterial species commonly associated with peritonitis were used: Staphylococcus aureus (CMCC(B) 26001), Staphylococcus epidermidis (ATCC 12228), and beta hemolytic Streptococcus (CMCC(B) 32210). Two Gram negative bacteria commonly associated with peritonitis were selected: E. coli 0157:H7 (ATCC35150) and Pseudomonas aeruginosa (ATCC 27853). Bacteria were cultured on plate media. After they were enriched, the colony was moved to phosphate buffer from the plate media. Bacteria concentration was determined using McIntosh turbidity. Each concentrated bacteria solution was spiked to 10 individual PDEs. For Staphylococcus aureus, Staphylococcus epidermidis and Beta hemolytic Streptococcus, the bacteria was diluted to 1×10{circumflex over ( )}7 CFU/ml. E. coli O157:H7 was diluted to 5×10{circumflex over ( )}6 CFU/ml. P. aeruginosa was diluted to 1×10{circumflex over ( )}9 CFU/ml. A total of 50 spiked peritonitis samples were generated. 30 PDEs were “spiked” with Gram positive bacteria. 20 PDEs were spiked with Gram negative bacteria. Each sample was tested with an LTA test and LPS test. The testing results were summarized in the following table:
-
TABLE C Limit of Detection for LTA and LPS in Gram Positive and Gram Negative Bacteria Spiked PD Samples LTA LPS Gram Bacteria CFU/ml Negative Positive Negative Positive Positive S. aureus 1 * 107 0/10 10/10 10/10 0/10 S. epidermidis 1 * 107 0/10 10/10 10/10 0/10 streptococcus 1 * 107 0/10 10/10 10/10 0/10 Negative E coil O157: H7 5 * 106 10/10 0/10 0/10 10/10 P. aeruginosa 1 * 109 10/10 0/10 0/10 10/10 - The sensitivity of LTA for Gram positive bacteria was 30/30=100%. The sensitivity of LPS for Gram negative bacteria was 20/20=100%. No cross reaction was found between Gram positive strains and the LPS test, or between Gram negative strains and the LTA test.
- An additional 19 non-peritonitis PDE samples were recruited and tested for NGAL, IL-6, LTA, and LPS specificity as described in Example IV, using Magpix for quantitation of NGAL and IL-6. Table D shows the results:
-
TABLE D Specificity for NGAL, IL-6, LTA, and LPS in Peritoneal Dialysis Effluents NGAL IL-6 200 NGAL/IL-6 200 LTA LPS Testing number 19 19 19 19 19 Negative result 18 19 19 19 19 Specificity 18/19 19/19 19/19 19/19 19/19 94.7% 100.0% 100.0% 100.0% 100.0% - The combination of NGAL80 ng/ml & IL-6 200 pg/ml presents 100% specificity with 19 PDEs from normal patients. LTA and LPS tests also presents 100% specificity with the 19 PDEs.
- The results of Example V and Example IV were compiled to derive a composite sensitivity and specificity as shown in Tables E, F, and G.
-
TABLE E Combined Specificity NGAL IL-6 200 NGAL/IL-6 200 LTA LPS Testing number 97 97 97 97 37 Negative result 74 85 89 94 37 Specificity 74/97 85/97 89/97 94/97 37/37 76.3% 87.6% 91.8% 96.9% 100.0% -
TABLE F Combined Sensitivity NGAL/IL-6 NGAL IL-6 200 200 Testing number 9 9 9 Positive result 9 9 9 Sensitivity 9/9 9/9 9/9 100.0% 100.0% 100.0% -
TABLE G Total Agreement for Both Positive and Negative PDE Samples NGAL/IL-6 NGAL IL-6 200 200 Testing number 106 106 106 Agreement number 83 94 98 Total 83/106 94/106 98/106 Agreement 78.3% 88.7% 92.5% - The assay showed a good ability to detect peritonitis in PDE samples, with specificity of 91.8% and sensitivity of 100%. The assay also indicated the specific type of pathogen of infection. The most frequent bacterial pathogens associated with peritonitis can be detected and distinguished as Gram negative or Gram positive.
- Specific Detection and Treatment
- The assay/assay kit as described above (e.g., such as shown in
FIGS. 1 through 5 ) is modified to include a binding molecule that specifically binds to an antigen indicative of the presence of a specific pathogen species, in this example, Staphylococcus aureus by substituting antibodies specific for S. aureus (e.g., ab37644 from Abcam, catalog number 15704 from QED Bioscience, Inc., or C55570M from Meridian Life Science, Inc.) for one of the antibodies used in the standard assay (i.e., specific for LTA, LPS, NGAL, IL-6, or β-glucan). When a subject is determined to be suffering from peritonitis caused by S. aureus, the subject is administered appropriate antibiotic therapy (e.g., cotrimoxazole) to treat the peritonitis in view of the diagnosis. - The assay/assay kit as described in
FIGS. 1 and 2 [having four parallel lanes] was modified to include an antibody that specifically binds to the peptidoglycan antigen of Staphylococcus aureus (MA1-10708 and MA1-10709 from Invitrogen, Inc.), instead of the LTA-specific antibody. “Non-peritonitis” PDE samples (PDE 83-88) (n=6), PDE samples spiked with varying concentrations of S. aureus (n=6), and a peritonitis-positive PDE sample known to be culture positive for S. aureus (n=1) were analyzed using the modified assay as described. The results are shown in the Table below. -
TABLE D S. aureus specific analysis Non-peritonitis PDE 83 Negative PDE 84 Negative PDE 85 Negative PDE 86 Negative PDE 87 Negative PDE 88 Negative Staphylococcus aureus 5 * 10{circumflex over ( )}4 Negative CFU/ml 1 * 10{circumflex over ( )}5 Negative CFU/ml 1 * 10{circumflex over ( )}6 Positive CFU/ml 1 * 10{circumflex over ( )}7 Positive CFU/ml 1 * 10{circumflex over ( )}8 Positive CFU/ml 1 * 10{circumflex over ( )}9 Positive CFU/ml Peritonitis (culture positive with PDE 80Positive S. aureus) - As can be seen, all “non-peritonitis” samples tested negative for S. aureus (100% specificity). Peptidoglycan specific to S. aureus was detected in the spiked samples, with a limit of detection of 1×106 CFU/ml, as well as in the S. aureus culture positive PDE sample.
- As illustrated in
FIG. 8 , the decision tree/protocol is initiated by a turbidity test, which can be patient/practitioner initiated (as using a visual inspection or cell-phone based scan of the dialysis bag) or can be monitored using one or more sensors integrated with the dialysis bag or tubing. Examples of turbidity methods that may be suitable for use in the present disclosure may be found in PCT Publication WO2018/007013, filed Jul. 7, 2017 and titled “Method and Smartphone for Detecting Symptoms of Peritonitis,” the contents of which are incorporated herein by this reference. This decision tree can be initiated even in the absence of symptoms, permitting a possibly earlier detection of infection than is customarily seen in current practice. If turbidity is positive 20, samples of the PD effluent are applied to the disclosed device to evaluate Gram status. Appropriate antibiotic therapy can be rapidly initiated based on a Gram+ or Gram− result, or the patient can be directed to further evaluation by a clinician if Gram status is inconclusive. If the POCT test is negative 32 with a positive turbidity test, the patient can be directed to take no further action (assuming symptoms are absent) or to seek further clinical evaluation 34 (e.g., depending on the breadth of the POCT in detecting, for instance, fungal infections). - In similar fashion for this decision tree, if turbidity is negative or inconclusive 36, then the presence of
symptoms 38 will determine whether the POCT device should be deployed. - Symptom-Driven Patient Decision Tree
- As illustrated in
FIG. 9 , this decision tree is primarily symptom-driven and may be utilized for example in situations where turbidity is not captured automatically or where patients are not routinely performing turbidity tests after treatment. - In this approach, the presence of one or
more symptoms 62 of infection would indicate that a turbidity test be taken. If turbidity is positive or not available 68, the patient would then be directed to use the POCT device. If the POCT device reports either a Gram+ or Gram− bacterium is present, appropriateantibiotic therapy clinical evaluation 66. One advantage of this protocol, however, is that a symptomatic patient withturbidity 68 will be able to make a rapid determination of the likely cause of infection (Gram+ or Gram−, or even the specific bacterial, fungal, or other agent), before even presenting to the clinician, allowing a much faster determination of appropriate treatment. - In this approach, where symptoms are absent 58, the patient would be directed to take no
further action 60. However, in all cases where the patient is experiencing one ormore symptoms 62, the POCT device may recommend the patient to determine if a specific cause of infection is present. - The entire contents of all cited references are specifically incorporated by reference in this disclosure. Further, when an amount, concentration, or other value or parameter is given as either a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed.
- Other embodiments of the instant disclosure will be apparent to those skilled in the art from consideration of the present specification and practice of the instant disclosure disclosed herein. It is intended that the present specification and examples be considered as exemplary only with a true scope and spirit of the invention being indicated by the following claims and equivalents thereof.
Claims (32)
1. An assay kit for diagnosing an infection in a subject, the assay kit comprising:
at least one first binding molecule that specifically binds an inflammatory marker in a sample taken of the subject, wherein the inflammatory marker is selected from the group consisting of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor a (TNFα), and procalcitonin,
at least one second binding molecule having a label that specifically binds to the selected inflammatory marker or to the at least one first binding molecule,
at least one third binding molecule that specifically binds a marker indicative of the presence of a lipoteichoic acid (LTA) in the sample, and
at least one fourth binding molecule having a label that specifically binds to the marker indicative of the presence of LTA in the sample or to the at least one third binding molecule.
2. The assay kit of claim 1 , wherein the binding molecules have been incorporated into a lateral flow device.
3. An assay kit comprising:
a binding molecule that specifically binds an antigen indicative of a subject launching an inflammatory response in the peritoneum, wherein the antigen indicative of an inflammatory response in the peritoneum is selected from the group consisting of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor a (TNFα), and procalcitonin;
a binding molecule that specifically binds an antigen indicative of the presence of a Gram− positive bacteria;
a binding molecule that specifically binds an antigen indicative of the presence of Gram− negative bacteria; and
a binding molecule having a label that specifically binds an antigen indicative of the presence of a fungus.
4. The assay kit of claim 3 , wherein β-glucan is the antigen indicative of the presence of a fungus.
5. An assay kit comprising:
a binding molecule that specifically binds an antigen indicative of a subject launching an inflammatory response in the peritoneum wherein the antigen indicative of an inflammatory response in the peritoneum is selected from the group consisting of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor a (TNFα), and procalcitonin;
a binding molecule that specifically binds lipoteichoic acid (LTA); and
a binding molecule that specifically binds an antigen indicative of the presence of Gram− negative bacteria.
6. The assay kit of claim 5 , wherein lipopolysaccharide (LPS) is the antigen indicative of the presence of Gram− negative bacteria.
7. The assay kit of claim 5 , further comprising:
a binding molecule that specifically binds an antigen indicative of the presence of a specific pathogen species in a peritoneal dialysis effluent.
8. The assay kit of claim 7 , wherein the specific pathogen is selected from the group consisting of Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, a Coagulase-negative staphylococcal species Staphylococcus epidermidis, Staphylococcus haemolyticus, a Streptococcus sp., an Escherichia coli, a Candida sp., an Aspergillus spec., and a vancomycin-resistant Enterococcus.
9. The assay kit of claim 5 , further comprising:
means for filtering, concentrating and/or enriching antigen(s) from peritoneal dialysis effluent.
10. The assay kit of claim 5 , further comprising:
a buffer that elutes antigen(s) from a sample from a subject.
11. The assay kit of claim 5 , further comprising:
a binding molecule that specifically binds peptidoglycan (PGN).
12. A method of diagnosing peritonitis in a subject who is a peritoneal dialysis patient, the method comprising:
diagnosing the subject as having peritonitis comprising utilizing the assay kit of claim 5 to analyze the subject's peritoneal dialysis effluent.
13. A method of treating peritonitis in a subject who is a peritoneal dialysis patient, the method comprising:
diagnosing the subject as having peritonitis comprising utilizing the assay kit of claim 5 to analyze the subject's peritoneal dialysis effluent and diagnose peritonitis, and
administering an appropriate antibiotic to the subject to treat the peritonitis.
14. The method according to claim 13 , further comprising:
processing results of the diagnosis electronically with a digital application.
15. The method according to claim 14 , further comprising:
transmitting the electronically processed results to a healthcare practitioner.
16. A method of using the assay kit of claim 5 to diagnose peritonitis in a peritoneal dialysis patient, the method comprising:
using the binding molecule that specifically binds an antigen indicative of a subject launching an inflammatory response in the peritoneum to detect in a peritoneal dialysis effluent from the subject an antigen indicative of the subject having launched an inflammatory response in the peritoneum that may be present in the peritoneal dialysis effluent;
using the binding molecule that specifically binds LTA to detect in the peritoneal dialysis effluent an antigen indicative of the presence of Gram− positive bacteria that may be present in the peritoneal dialysis effluent; and
using the binding molecule that specifically binds an antigen indicative of the presence of Gram− negative bacteria to detect in the peritoneal dialysis effluent an antigen indicative of the presence of Gram− negative bacteria that may be present in the peritoneal dialysis effluent.
17. The method according to claim 16 , further comprising:
detecting in the peritoneal dialysis effluent an antigen indicative of the presence of a fungus.
18. The method according to claim 16 , wherein lipopolysaccharide (“LPS”) is the antigen indicative of the presence of Gram− negative bacteria.
19. The method according to claim 17 , wherein β-glucan is the antigen indicative of the presence of a fungus.
20. The method according to claim 16 , further comprising:
detecting in the peritoneal dialysis effluent an antigen indicative of the presence of a specific pathogen species in a peritoneal dialysis effluent.
21. The method according to claim 20 , wherein the specific pathogen is selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Escherichia coli, a Candida sp., and a vancomycin-resistant Enterococcus.
22. The method according to claim 16 , further comprising:
filtering, concentrating, and/or enriching the peritoneal dialysis effluent prior to detecting antigen(s).
23. The method according to claim 16 , further comprising:
taking a picture of results of the method and transmitting the picture to a healthcare practitioner.
24. The method according to claim 16 , further comprising:
processing results of the method electronically.
25. The method according to claim 24 , further comprising:
transmitting the electronically processed results to a healthcare practitioner.
26. A method of diagnosing peritonitis in a peritoneal dialysis patient, the method comprising:
detecting turbidity in peritoneal dialysis effluent of the subject; and
using a binding molecule that specifically binds LTA to detect in the peritoneal dialysis effluent an antigen indicative of a pathogen present in the peritoneal dialysis effluent.
27. The method according to claim 26 , wherein the pathogen is selected from the group consisting of a Gram− negative bacterium, a Gram− positive bacterium, a fungus, and a combination of any thereof.
28. The method according to claim 27 , further comprising:
treating the subject with an antibiotic appropriate for the detected pathogen.
29. The method according to claim 26 , further comprising:
using a binding molecule that specifically binds an antigen indicative of a subject launching an inflammatory response in the peritoneum to detect in a peritoneal dialysis effluent from the subject an antigen indicative of the subject having launched an inflammatory response in the peritoneum that may be present in the peritoneal dialysis effluent.
30. The method according to claim 29 , further comprising:
treating the subject with an antibiotic appropriate for the detected pathogen.
31. The method according to claim 27 , further comprising:
using a binding molecule that specifically binds an antigen indicative of a subject launching an inflammatory response in the peritoneum to detect in a peritoneal dialysis effluent from the subject an antigen indicative of the subject having launched an inflammatory response in the peritoneum that may be present in the peritoneal dialysis effluent.
32. The method according to claim 31 , further comprising:
treating the subject with an antibiotic appropriate for the detected pathogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/498,481 US20220042988A1 (en) | 2019-01-31 | 2021-10-11 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962799430P | 2019-01-31 | 2019-01-31 | |
US16/752,518 US11280788B2 (en) | 2019-01-31 | 2020-01-24 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
US17/498,481 US20220042988A1 (en) | 2019-01-31 | 2021-10-11 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,518 Continuation US11280788B2 (en) | 2019-01-31 | 2020-01-24 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220042988A1 true US20220042988A1 (en) | 2022-02-10 |
Family
ID=71836247
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,518 Active US11280788B2 (en) | 2019-01-31 | 2020-01-24 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
US17/498,481 Pending US20220042988A1 (en) | 2019-01-31 | 2021-10-11 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/752,518 Active US11280788B2 (en) | 2019-01-31 | 2020-01-24 | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Country Status (5)
Country | Link |
---|---|
US (2) | US11280788B2 (en) |
EP (1) | EP3918330A4 (en) |
CN (1) | CN113383234A (en) |
TW (1) | TW202215053A (en) |
WO (1) | WO2020160040A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11280788B2 (en) * | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
CN115480061A (en) * | 2021-05-31 | 2022-12-16 | 费森尤斯医疗护理德国有限责任公司 | Use of H-NGAL for detecting peritonitis |
CN112198313A (en) * | 2020-09-27 | 2021-01-08 | 武汉菲恩生物科技有限公司 | Kit for PEA detection and use method thereof |
CN117120614A (en) | 2021-02-04 | 2023-11-24 | 费森尤斯医疗保健控股公司 | Lipopolysaccharide (LPS) aptamer and related methods |
EP4288545A1 (en) | 2021-02-04 | 2023-12-13 | Fresenius Medical Care Holdings, Inc. | Peptidoglycan (pgn) aptamers and associated methods |
CN117098845A (en) | 2021-02-04 | 2023-11-21 | 费森尤斯医疗保健控股公司 | Lipoteichoic acid (LTA) aptamer and related methods |
JP2024508550A (en) * | 2021-03-05 | 2024-02-27 | ゾエティス・サービシーズ・エルエルシー | Lateral flow assay for detecting pathogens in the milk of mastitis cows |
CN113791210A (en) * | 2021-09-17 | 2021-12-14 | 石家庄洹众生物科技有限公司 | Reagent strip and device for simultaneously detecting matrix metalloproteinase-8 and interleukin-6 and application thereof |
GB202216036D0 (en) * | 2022-10-30 | 2022-12-14 | Wilson Alistair Richard Ian | A diagnostic device for the early identification of microbial infection types, in biological samples |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006119308A2 (en) * | 2005-05-02 | 2006-11-09 | Bioscale, Inc. | Method and apparatus for detecting analytes using an acoustic device |
US20070092911A1 (en) * | 2005-10-03 | 2007-04-26 | Buechler Kenneth F | Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes |
US20140242613A1 (en) * | 2013-02-27 | 2014-08-28 | Kimberly-Clark Worldwide, Inc. | Rapid identification of organisms in bodily fluids |
US20150241424A1 (en) * | 2012-10-05 | 2015-08-27 | Gregory M. Lawrence | Multi-analyte assay |
WO2018060708A1 (en) * | 2016-09-30 | 2018-04-05 | Microbiosensor Limited | Methods and devices |
US11280788B2 (en) * | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3887771C5 (en) | 1987-04-27 | 2009-06-04 | Inverness Medical Switzerland Gmbh | Immunoassays and devices therefor. |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US6924153B1 (en) | 1997-03-06 | 2005-08-02 | Quidel Corporation | Quantitative lateral flow assays and devices |
US7118857B2 (en) * | 2004-02-27 | 2006-10-10 | Baxter International Inc. | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
WO2006071247A2 (en) | 2004-03-30 | 2006-07-06 | California Institute Of Technology | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots |
US8128871B2 (en) | 2005-04-22 | 2012-03-06 | Alverix, Inc. | Lateral flow assay systems and methods |
GB0420466D0 (en) | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
EP1849001B1 (en) | 2005-02-18 | 2016-04-06 | Charm Sciences, Inc. | Lateral flow test kit and method for detecting an analyte |
WO2009063307A2 (en) | 2007-11-14 | 2009-05-22 | Bio-Technology General (Israel) Ltd. | Inflammatory activity detection method using il-6 |
US8962260B2 (en) * | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
NZ616921A (en) | 2009-07-15 | 2015-06-26 | Genentech Inc | Gram-positive bacteria specific binding compounds |
GB201304626D0 (en) * | 2013-03-14 | 2013-05-01 | Univ Cardiff | Method of identifying a bacterial infection |
DE102014223430B4 (en) | 2014-11-17 | 2022-03-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Competitive immunoassay test system for the detection of a pyrogen |
GB201520657D0 (en) * | 2015-11-23 | 2016-01-06 | Mologic Ltd | Improvements in or relating to the detection of peritoneal Diaysis Fluid infection |
DE102016008332A1 (en) | 2016-07-07 | 2018-01-11 | Fresenius Medical Care Deutschland Gmbh | Method for detecting symptoms of peritonitis |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
-
2020
- 2020-01-24 US US16/752,518 patent/US11280788B2/en active Active
- 2020-01-28 WO PCT/US2020/015477 patent/WO2020160040A1/en unknown
- 2020-01-28 CN CN202080011833.1A patent/CN113383234A/en active Pending
- 2020-01-28 EP EP20749614.2A patent/EP3918330A4/en active Pending
- 2020-01-30 TW TW109102865A patent/TW202215053A/en unknown
-
2021
- 2021-10-11 US US17/498,481 patent/US20220042988A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006119308A2 (en) * | 2005-05-02 | 2006-11-09 | Bioscale, Inc. | Method and apparatus for detecting analytes using an acoustic device |
US20070092911A1 (en) * | 2005-10-03 | 2007-04-26 | Buechler Kenneth F | Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes |
US20150241424A1 (en) * | 2012-10-05 | 2015-08-27 | Gregory M. Lawrence | Multi-analyte assay |
US20140242613A1 (en) * | 2013-02-27 | 2014-08-28 | Kimberly-Clark Worldwide, Inc. | Rapid identification of organisms in bodily fluids |
WO2018060708A1 (en) * | 2016-09-30 | 2018-04-05 | Microbiosensor Limited | Methods and devices |
US11280788B2 (en) * | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
Non-Patent Citations (4)
Title |
---|
Brauner et al, American Journal of Kidney Diseases, vol 27, No 3, 1996: 402-408. (Year: 1996) * |
Lin et al. 2013 (Pathogen-Specific Local Immune Fingerprints Diagnose Bacterial Infection in Peritoneal Dialysis Patients; J. Am. Soc. Nephrol. 24:2002-2009) (Year: 2013) * |
Martino et al, Peritoneal Dialysis International (2015), vol. 35, 559-565. (Year: 2015) * |
Yang et al, Am J Nephrol 2018; 47:317-324. (Year: 2018) * |
Also Published As
Publication number | Publication date |
---|---|
TW202215053A (en) | 2022-04-16 |
CN113383234A (en) | 2021-09-10 |
WO2020160040A1 (en) | 2020-08-06 |
EP3918330A1 (en) | 2021-12-08 |
EP3918330A4 (en) | 2022-11-09 |
US11280788B2 (en) | 2022-03-22 |
US20200249228A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11280788B2 (en) | Rapid diagnosis of peritonitis in peritoneal dialysis patients | |
US9910036B2 (en) | Method and device for combined detection of viral and bacterial infections | |
RU2617400C2 (en) | Method for specific substance detection in milk | |
JP2019164143A (en) | Method and device for combined detection of viral and bacterial infections | |
Garcia et al. | Sensitivity and specificity of a blood and urine galactomannan antigen assay for diagnosis of systemic aspergillosis in dogs | |
US20210108250A1 (en) | Methods and devices for accurate diagnosis of infections | |
EP2335072A2 (en) | Method and device for combined detection of viral and bacterial infections | |
JP6784669B2 (en) | Methods and systems for identifying irritable bowel syndrome from inflammatory bowel disease and celiac disease | |
US20200209238A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
EP2841593B1 (en) | Clostridium difficile dehydrogenase and toxin as a biomarker | |
US20210364515A1 (en) | Optimizing diagnostics for galactofuranose containing antigens | |
JP6858784B2 (en) | Subtractive Immunoassay Assay Method and Lateral Flow Immunochromatography Assay Strip for Performing the Method | |
WO2016161413A1 (en) | Urinary tract infection biomarkers | |
US20220026426A1 (en) | System for determining peritonitis using homodimer neutrophil gelatinase-associated lipocalin | |
Svobodova et al. | Affiblot: a dot blot-based screening device for selection of reliable antibodies | |
WO2022253173A1 (en) | H-ngal for the detection of peritonitis | |
US20180196042A1 (en) | Homogeneous competitive lateral flow assay | |
RU2735983C1 (en) | Method for express analysis in vitro of antibiotic sensitivity of bacteria and fungi in patient | |
WO2022054754A1 (en) | Method for immunologically analyzing sepsis-causing bacteria, and monoclonal antibody used in said method | |
US20240077480A1 (en) | Lateral flow assay for detecting pathogens in milk from mastitic cows | |
Beberashvili et al. | A single center, open‐label, randomized, parallel group study assessing the relationship between asymptomatic bacteriuria and inflammation in maintenance hemodialysis patients | |
Lawton | Development of a rapid immunoassay for human pathogenic markers | |
Dobrut et al. | Development of a prototypic, field-usable diagnostic tool for the detection of gram-positive cocci-induced mastitis in cattle | |
JP2007300817A (en) | Method for detecting bacteria, detection reagent and detection kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |